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ABSTRACT 
Human African Trypanosomiasis (HAT) is an infectious, vector-borne protozoal disease which is 
amongst the so-called neglected diseases. In 2000, at a summit of the United Nations, eight 
Millennium Development Goals (MDGs) were set, to be achieved by 2015. MDG 6 states “to 
combat HIV/AIDS, malaria & other diseases”. With just under 2 years to go before the end of 
2015, HAT is still thriving in developing countries. The drugs currently used for the treatment of 
HAT are in short supply, have severe side effects and those used to treat late stages of the disease 
are very difficult to administer. The aforementioned challenges call for research into this 
neglected disease in order to develop new, safe and easy-to-use medicines.  
Naphthoquinones are a class of compounds shown to possess anti-parasitic activity, amongst a 
variety of other biological activities, and therefore this pharmacophore was selected for this 
study. The purpose of this study was to synthesise derivatives of 2,3-dichloro-1,4-
naphthoquinone to be tested for anti-trypanosomal activity and thereafter conduct structure-
activity relationship studies. A series of reactions were carried out using thiophenol, phenol and 
aniline nucleophiles to synthesise thioether (-S-), ether (-O-) and amino (-NH-) derivatives of 
2,3-dichloro-1,4-naphthoquinone with various halogen or methyl substituents. Purification of the 
products was carried out by recrystallisation. Nuclear magnetic resonance (NMR), infra-red (IR) 
and high pressure liquid chromatography coupled to an electro-spray ionisation mass 
spectrometer (HPLC-ESI-MS) were the analytical methods used for structural confirmation of 
the products.                                                                                               
There were eighteen 1,4-naphthoquinone derivatives that were successfully synthesised using 
ethanolic solutions. Unfortunately, attempts to synthesise 1,4-naphthoquinones in reactions 
involving 2-(trifluoro-methyl)aniline and 2-isopropyl-5-methylphenol were unsuccessful, 
presumably due to steric hindrance by the bulky ortho-substituents.  
Although the aims of the synthetic procedures were to obtain both mono- and disubstituted 
products by nucleophilic displacement of the chlorine atom(s) of 2,3-dichloro-1,4-
naphthoquinone, only monosubstituted products were obtained from substitution with aniline and 
phenol nucleophiles. Thiol nucleophiles, however, selectively yielded disubstituted products 
only.   
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Synthesised naphthoquinone derivatives were tested against Trypanosoma brucei and calculation 
of the EC50 values from the obtained dose-response curves was carried out using the four 
parametric equation. All the 1,4-naphthoquinones showed a degree of potency, except 
compounds 1b, 3c and 3e, which had little or lack of potency.                                                                                                                             
Structure-activity relationship studies (SARs and QSARs) were carried out to determine which 
structural features or functional group substituents of the naphthoquinone derivatives contribute 
or take away from the desired anti-trypanosomal activity. 
It was found that compounds with the best in vitro anti-trypanosomal potencies in the series of 
analogous 1,4-naphthoquinone derivatives had EC50 values in the range 2.137 to 2.884 µM. The 
most potent compound in the series was 2-chloro-3-(4-(trifluoromethyl)phenylamino)-1,4-
naphthoquinone 1e; but it was 142-fold less potent than the reference standard of melarsoprol.  
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CHAPTER I: LITERATURE REVIEW 
 
1.1 INTRODUCTION 
Human African Trypanosomiasis (HAT) - also known by its common name “sleeping 
sickness”*, is a vector-borne parasitic disease that is reported in 36 sub-Saharan African 
countries.
1
 It is amongst the so-called neglected tropical diseases. The causative organism of 
HAT is a protozoan parasite of the taxonomic order Kinetoplastida of the Trypanosoma 
brucei species. The two sub-species that are common in sub-Saharan Africa are Trypanosoma 
brucei gambiense and Trypanosoma brucei rhodesiense, with the former being accountable 
for 90% of the reported cases of the disease.
2,3
 In west and central Africa, Trypanosoma 
brucei gambiense is the sub-species that causes the most prevalent form of the disease, whilst 
the Trypanosoma brucei rhodesiense sub-species is prevalent in the eastern and southern 
parts of Africa.
1
 Trypanosomes, parasites that cause HAT, are transmitted through a vector,  
the tsetse fly, that belongs to the Glossina genus.
4
  
Sleeping sickness, which may lead to fatalities if untreated, occurs in two clinical stages. 
Stage 1, which is also known as the hemolymphatic stage, occurs early on and it involves the 
presence of trypanosomes in the haemolymphatic system. Non-specific symptoms such as 
malaise, fever, headaches and peripheral oedema are typical of stage 1. Stage 2, occurs later 
on and is also called the neurological or meningoencaphalic stage. It is depicted by 
neurological symptoms such as behavioural changes, convulsions and sleeping disorders. It is 
from the sleeping disorders that HAT derived its common name of sleeping sickness. It is 
only after the trypanosomes cross the blood-brain barrier into the brain that stage 2 occurs. At 
this stage, if the patient does not receive any treatment, the disease progresses and death may 
result. The treatment of HAT is prescribed based on the causative sub-species of the parasite, 
T.b gambiense or T.b rhodesiense, as well as the stage of the disease - either stage 1 or 2.
1
 In 
order to prescribe correctly, diagnostic tests to distinguish between the two types of parasites 
and the two forms of the disease are crucial.  
Availability of HAT medicines declined in the 1990s as the pharmaceutical industry had 
stopped production due to non-profitability, amongst other reasons.
5
 The World Health 
Organization came to the rescue by establishing a public-private partnership with Sanofi-
                                               
*HAT and sleeping sickness will be used interchangeably 
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Aventis (now Aventis) and Bayer in the year 2000 which was renewed in the years to follow. 
This partnership saw the donation and distribution of medicines in countries where HAT is 
endemic. Efforts made by the World Health Organization (WHO) to curb waves of HAT 
epidemics might be paying off, as the organisation stated in its 2009 report that numbers of 
new cases in that year had dropped to below 10 000 for the first time in 50 years. Non-
governmental organisations such as Médecins Sans Frontières (Doctors Without Borders) 
have also been playing a pivotal role in the distribution of HAT medicines. 
5,6
     
 
1.2 EPIDEMIOLOGY OF SLEEPING SICKNESS  
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1.1: A map of Africa highlighting the regions affected by sleeping sickness. The black 
line demarcates the regions where the T.b gambiense sub-specie is prevalent (west and central 
Africa) from the regions of T.b rhodesiense (eastern and southern Africa). Countries with no 
colour allocation (white) are not considered endemic for the disease.  
Image Credit: Adapted from Simarro et al.
7
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Sleeping sickness is considered to be endemic in 36 sub-Saharan countries but reports in 
2011 stated that six of these (Botswana, Burundi, Ethiopia, Gambia, Namibia and Niger) had 
not reported any cases for two decades. Between 2000 and 2009,  a majority of the countries 
considered endemic for the disease received support from either WHO alone or from both 
WHO and non-governmental organisations.
8
   
 In addition to ensuring the availability of these medicines in the endemic countries, WHO 
also provides support in terms of assessing the epidemiological status of HAT or by 
establishing control and surveillance programmes in line with the 1997 World Health 
Assembly elimination resolution.
6-9
 
In its 2009 report, WHO stated that the number of new cases that year had dropped to below 
10 000 for the first time in 50 years, showing that efforts made by the organisation in curbing 
the waves of HAT epidemics might be paying off.
6,8
  
Land-mapping and tsetse fly (vector) distribution is similar to the disease mapping shown in 
the African map in Figure 1.1 above.
10
 Tsetse flies are inhabitants of mainly the mid-
continent of Africa (south of the Sahara and north of the Kalahari) and are needed for the 
transmission of the disease. HAT is thus a health burden in regions where tsetse flies are 
found.
4,9
    
 
1.3 LIFECYCLE OF TRYPANOSOMES  
There are typically three parties that harbour the trypanosomes which cause both types of 
sleeping sickness namely tsetse flies, humans and wild/domestic animals. Tsetse flies ingest 
trypanosomes by taking a blood meal from an infected host and become infective about three 
weeks later. During these three weeks, the ingested parasites go through a series of 
morphological and biochemical changes in the midgut of the tsetse fly. Modified parasites 
then move from the midgut to the salivary glands where they become infective metacyclic 
trypanosomes transmitted through another blood meal. The trypanosomes then enter the 
host’s bloodstream, lymph nodes and if untreated they can end up in the central nervous 
system. The parasites also undergo transformation in the human body just like in the tsetse fly 
(Figure 1.2). One of the most crucial components of the disease is contact between a human 
and a tsetse fly. Once a fly becomes infected, it remains a vector for the rest of its life posing 
as one of the biggest challenges in disease control.
11
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Figure 1.2: The lifecycle of Trypanosoma brucei in the human and tsetse fly. Adapted and 
re-drawn from Centers for Disease Control and Prevention.
12
      
    
 
 
 
 
 
 
 
 
                                                                                      CHAPTER I: LITERATURE REVIEW    
 
5 
 
1.4 BIOCHEMISTRY OF TRYPANOSOMES 
Trypanosomes and other protozoan parasites have been shown to possess a unique form of 
glutathione called trypanothione. Trypanothione consists of two glutathione molecules joined 
by spermidine, a polyamine linker. Trypanothione is the parasite equivalent of gluthathione 
and is essential for the survival of these parasites. There are enzymes that rely on 
trypanothione, known as trypanothione-dependent enzymes, and these include reductase, 
peroxidase and transferase enzymes (Scheme 1.1). Trypanothione reductase is an NADPH-
dependent flavoenzyme which assists in defence against oxidative stress by upholding 
sufficient levels of trypanothione, which is responsible for the reduction of hydroperoxides. 
Gluthathione reductase is the human equivalent and it plays a similar role against oxidative 
stress. Variation between these two systems and differences in their enzyme active sites has 
been explored as a possible drug target which could offer selective toxicity. The end result of 
the inhibition of trypanothione reductase would be a reduction in trypanothione levels and 
thus oxidative stress.  New agents that selectively inhibit trypanothione reductase enzyme 
with less toxicity would be advantageous.
13,14
  
 
NADPH
NADP+
Try[S]2
Try[SH]2
TryX[SH]2
TryX[S]2
R-OOH
R-OH + H2O
TryR TryX TryP
direction of movement of electrons
terminal electron
acceptor
peroxide
 
Scheme 1.1: NADPH-dependent redox cycle. TryR = trypanothione reductase enzyme, 
Try[SH]2 = trypanothione, TryX = tryparedoxin enzyme, TryP = tryparedoxin peroxide 
enzyme, R-OOH = alkyl hydroperoxide. Adapted and re-drawn from Flohé et al.
14
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1.5 PREVENTION AND CONTROL OF SLEEPING SICKNESS    
Efforts to develop a vaccine for sleeping sickness have been unsuccessful mainly due to the 
complexity of the biology of the trypanosomes where an antigen variation mechanism has 
hindered the development of vaccines. There are no available drugs for prophylaxis against 
sleeping sickness.
2,15
   
Vector control programmes have long been thought to offer great hope in the curbing of 
sleeping sickness. Tsetse flies are ubiquitous, making their eradication a challenge. However, 
measures have been put in place to control this vector and efforts have been made to try to 
break the transmission cycle.
2
 Various approaches explored in trying to control the tsetse flies 
include insecticide spraying, which has been successful but gives rise to ecological 
considerations that hamper their use. The use of tsetse traps impregnated with attractants has 
also been explored.
2
 Another means of vector control is releasing sterile male tsetse flies in a 
bid to promote unproductive mating with females. This method was effective in eradicating 
Glossina austeni from a small island off the coast of Tanzania.
4
  
 
1.6 DIAGNOSIS AND STAGING OF SLEEPING SICKNESS  
The simplest means of parasite detection in blood is the use of a finger-prick test but this is 
the least sensitive method, with a detection limit of 10 000 parasites per millilitre. Diagnosis 
of sleeping sickness depends on identifying T.b gambiense or T.b rhodesiense trypanosomes 
and this clinical evidence of an infection still relies on visualisation of the parasites in blood, 
lymph and cerebrospinal fluid (CSF). Such evidence is provided by parasitological tests as 
well as light microscopy examinations. Concentration of parasites can be done to increase the 
sensitivity of the tests. Techniques that are used to do this include haematocrit centrifugation 
(HCT) with fluorescent detection of the parasites and the mini anion exchange centrifugation 
technique (mAECT). The mAECT allows for separation of the parasites from red blood cells 
before centrifugation is carried out. A major disadvantage of microscopy is that it does not 
provide information of whether the infection is caused by either the T.b gambiense or T.b 
rhodesiense trypanosomes. Discrimination between the two types of trypanosomes is critical 
as the effective selection of treatment depends on the causative sub-species. Therefore, once 
an infection with trypanosomes has been confirmed by microscopy, the next step is to carry 
out serological tests to discriminate between the two sub-species. The most practical 
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technique used to detect humoral response in blood, lymph and CSF is the card agglutination 
test for trypanosomiasis (CATT). CATT is capable of detecting an infection with T.b 
gambiense trypanosomes on the basis of a variable surface antigen type LiTat 1.3. There are 
short-comings with CATT; these include false positives and negatives, inability to indicate 
cure as the antibodies persist for long periods after treatment, it requires patient follow-ups 
and it only detects antibodies against T.b gambiense and not the T.b rhodesiense sub-
species.
7,16
  
Both T.b gambiense and T.b rhodesiense infections can progress from stage 1 
(haemolymphatic) to stage 2 (neurological) and again the choice of treatment is dependent on 
the causative sub-species as well as the stage of the disease.
11
 It is therefore critical that 
disease staging is carried out soon after parasite detection and identification.  Patients are 
staged upon examination of their CSF, requiring a lumbar puncture on the spine to collect a 
sample of the CSF. A white cell count of the CSF of less than 5 per microlitre and the 
absence of trypanosomes in the CSF is indicative of stage 1 HAT, whilst presence of 
trypanosomes in CSF and a white cell count of greater than 20 per microlitre are indicative of 
stage 2 HAT. 
11,16
 
Although the diagnosis and staging of HAT is a complex process that requires skilled 
personnel, it is very important for treatment success as the medicines are specific for a 
causative sub-species and disease staging. There is great need for new drugs that are effective 
against both T.b gambiense and T.b rhodesiense infections as well as drugs that are capable 
of treating both stage 1 and 2 HAT. The late stage of the disease requires drugs that can cross 
through the blood-brain barrier to attain effective concentrations in the brain. Such new drugs 
will enable us to do away with the painful, risky lumbar punctures for collecting CSF samples 
and also to cut down on the costs incurred during diagnosis.
1,4,17
 
 
1.7 CURRENT TREATMENT OR THERAPIES  
To date, there are only four drugs registered for the treatment of HAT, namely suramin, 
pentamidine, melarsoprol and eflornithine.
18
 The latter has also been registered as a 
combination therapy with a drug called nifurtimox which is used to treat another 
trypanosomal disease called Chagas disease.
19
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1.7.1 Suramin  
Suramin (shown in Figure 1.3) is a poly-anionic sulphonated napthylamine drug synthesised 
in 1916 and introduced in 1922.
3,20
 Suramin is still the drug of choice, nearly a century later, 
for the treatment of stage 1 of the T. b. rhodesiense form of the disease.
20
 The drug’s highly 
ionic nature does not enable it to cross the blood-brain barrier into the central nervous system 
(CNS) and it is therefore only useful for stage 1 of the disease which does not involve the 
CNS.
3,20
 
 Suramin is a highly water soluble drug that is administered intravenously. Upon 
administration, the immediate life-threatening side effects a patient may experience include 
nausea, vomiting and shock. Delayed severe side effects of suramin include renal 
malfunction, agranulocytosis, jaundice and exfoliative dermatitis. Suramin is highly protein 
bound in serum and this is responsible for its long half-life of 90 days; the drug also has a 
slow onset of trypanocidal action.
20
  The mode of action of suramin is unknown.
3,20
 Suramin 
is manufactured by Bayer and it is marketed under the trade name Germanin.
20
  
 
1.7.2 Pentamidine   
Pentamidine (shown in Figure 1.3) is an aromatic diamine compound synthesised in 1937 
and introduced in the 1940s. It is indicated for the treatment of stage 1 of the T.b. gambiense 
form of sleeping sickness. Its other indications include antimony-resistant leishmaniasis and 
Pneumocystis carinii infections in patients that are non-tolerant to trimethoprim-
sulfamethoxazole (co-trimoxazole). Pentamidine is administered parenterally owing to its 
protonation at physiological pH, which results in poor bioavailability when administered 
orally. The intramuscular route of administration is preferred to the intravenous as the latter 
route has been reported to cause severe hypotensive reactions. Serious side effects of 
pentamidine include liver, pancreas and kidney damage.  The drug’s mode of action is 
unclear, although several hypotheses have been put forward; including the inhibition of a 
plasma-membrane Ca
2+ 
ATPase in Trypanosoma brucei. Pentamidine is manufactured by 
Aventis and it is marketed under the trade name Lomidine.
20
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1.7.3 Melarsoprol  
Melarsoprol (shown in Figure 1.3)  is a melaminophenyl-based organic arsenical compound
3
 
that was the drug of choice for the treatment of stage 2 of either the T.b. gambiense form or 
the T. b. rhodesiense form of the disease. Melarsoprol, introduced in 1949, is manufactured 
by Aventis and sold under the trade names Mel B and Arsobal.
20
  
Melarsoprol is administered intravenously over a period of 10 days, thus requiring 
hospitalisation and medical supervision for the entire treatment duration.
3
 The drug is 
completely insoluble in water therefore; it is dissolved in an alcohol (propylene glycol) to 
facilitate intravenous administration. However, propylene glycol is extremely irritating to the 
tissue and causes thrombophlebitis at the site of injection.
20
  A fatal side effect of melarsoprol 
is reactive encephalopathy and it is reported that 5-10% of patients treated with the drug 
suffer from this serious complication.
3,20
 At least 1-5% of the patients die during the course 
of treatment as a result of the toxic nature of the drug.
21
 In order to minimise the chances of 
patients experiencing episodes of reactive encephalopathy, melarsoprol is co-administered 
with corticosteroids such as prednisolone.
3
 Discontinuation of melarsoprol is advised if a 
patient experiences convulsions or deterioration in mental state.
21
 
Melarsoprol is a pro-drug that is rapidly converted to its active metabolite, melarsen oxide, 
which has an elimination half life of 3.5 hours.
3
 The mode of action of melarsoprol on 
trypanosomes is unknown, although several hypotheses have been put forward. These include 
competitive inhibition of an enzyme crucial to the parasites called trypanothione reductase as 
well as the rapid and selective uptake through the P2-purine transporter which contributes to 
selective toxicity.
3,20
 
 
1.7.4 Eflornithine Monotherapy 
Eflornithine (shown in Figure 1.3) is an ornithine analogue whose mode of action is the 
irreversible inhibition of ornithine decarboxylase, a polyamine biosynthetic enzyme.
3
 
Registered in 1990
7
, eflornithine is manufactured by Aventis;  it is the only new candidate 
registered for the treatment of HAT in the last 50 years
15
and is sold under the trade name 
Ornidyl.
20
 Eflornithine is the drug of choice for the treatment of stage 2 of HAT caused by 
T.b. gambiense. This drug is less effective against T. b. rhodesiense HAT and is therefore not 
recommended for this form of the disease.
3,20
 Eflornithine has its own shortcomings that 
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include difficult intravenous administration of 4 times daily infusions for 14 days and high 
costs of the drug. It is critical that the infusion be administered slowly over 2 hours and this 
requires the patient to be hospitalised for the entire duration of treatment.
20,21
 The frequent 
administration of the drug is due to its short plasma half-life of 3 hours.
3
 Side effects of 
eflornithine include fever, headaches, hearing loss, facial oedema, convulsions, dizziness, 
anaemia as well as gastrointestinal problems such as vomiting and diarrhoea.
3,21
 
 
1.7.5 Nifurtimox Eflornithine Combination Therapy (NECT)   
Combination therapy of nifurtimox and eflornithine (shown in Figure 1.3) was introduced in 
2009 for the treatment of stage 2 HAT caused by T.b. gambiense and was added to the World 
Health Organization’s Essential Medicines List in the same year.19,22 Nifurtimox is an oral 
drug used for the treatment of Chagas disease, another trypanosomal disease, also known as 
American trypanosomiasis.
19
 NECT is the only major advancement that has occurred in the 
course of 25 years in the treatment of sleeping sickness.
1,18
 The combination improved and 
simplified administration of the intravenous course of eflornithine from four times daily 
infusions for 14 days to twice daily infusions for 7 days. Thus the combination treatment has 
reduced the number of eflornithine doses from four daily doses with the entire course 
comprising of 56 doses, to two daily doses, which adds up to 14 doses for the entire treatment 
course.
19
 The treatment course with NECT and the hospital stay are therefore shorter which is 
useful in the resource-deprived settings affected by HAT.
23
 The shorter treatment course has 
a huge impact on the cost of treatment, as intravenous drugs are expensive and combining 
with an already cheap oral drug lowers costs.
23
 Yun et al. (2010)
19
 reported the cost of NECT 
kits to be €39 per patient, which was almost three times cheaper than eflornithine 
monotherapy kits, which cost €107 per patient.19 Reduction in toxicity and a possible delay in 
the emergence of drug-resistance are some of the advantages of this combination therapy.
23
 
Although it is an improvement to current HAT therapies, NECT has its short-comings. There 
is still need for intravenous infusions of eflornithine despite the reduction in the number of 
doses and the need for trained care-givers is still inevitable.
1,19
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Figure 1.3: Structures of drugs used in the treatment of Human African Trypanosomiasis 
(sleeping sickness).  
 
1.8 LIMITATIONS OF CURRENT TREATMENT 
Melarsoprol, eflornithine and suramin all require intravenous administration whilst 
pentamidine requires intramuscular administration. This means that patients need to be 
hospitalised for the treatment of HAT - a challenge, considering that HAT mainly affects 
rural populations which are, in most cases, in remote areas. The disease also thrives in the 
war torn regions of central Africa. In addition, nifurtimox is the only orally administered drug 
used for HAT at present.  
Adverse events resulting from treatment with HAT therapies are fatal and life-threatening. 
For example, 5-10% of the patients treated with melarsoprol suffer from serious 
complications with the most frequent complication being reactive encephalopathy. Treatment 
failures are also being reported and this calls for research into safe and effective therapies.
3
  
There is a need for therapies that cross the blood-brain barrier with ease and concentrate in 
the brain to treat the neurological stages (stage 2) of the disease. Suramin, the drug of choice 
for the treatment of stage 1 of the T. b. rhodesiense form of the disease, has minimal 
permeation across the blood-brain barrier and this limits its use to the treatment of stage 1 
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only.
3
 With melarsoprol, its active metabolite permeates through the blood-brain barrier but 
up to 1-2% of maximum plasma concentration is attained. 
3
 
Cost effective therapies are also crucial and high costs may be reduced through the 
development of orally administered therapies as opposed to expensive intravenous therapies. 
Costs may be further reduced if patients are treated by oral drugs whilst staying at home.  
 
1.9 THERAPIES IN THE PIPELINE  
1.9.1 Fexinidazole  
The year 2006 saw the rediscovery of a potential drug candidate which was never pursued in 
the 1980s.
1,3
 Fexinidazole is a promising orally administered treatment for sleeping sickness. 
This potential candidate entered phase I of clinical trials in 2009 and is currently in phase 
II/III trials. It is the first new drug candidate for stage 2 of sleeping sickness to enter these 
trials in the last 30 years. An organisation called the Drugs for Neglected Disease initiative 
(DNDi) carried out an extensive compound mining and profiling of more than 700 
nitroheterocyclic compounds, the majority of which were nitroimidazoles. Compounds were 
assessed for their anti-parasitic and mutagenic potential. After a systematic review of these, 
fexinidazole, a 2-substituted 5-nitroimidazole, showed potential and was a promising 
candidate for the treatment of sleeping sickness. Fexinidazole had reached pre-clinical 
development as a broad spectrum antimicrobial agent in the late 1970s and early 1980s, and 
the work was conducted by Hoechst AG which became Sanofi-Aventis. At that time, 
fexinidazole had been favoured amongst a series of compounds because of the relative ease 
of its chemical synthesis, the broad spectrum of its action as well as its low toxicity profile.
1
  
                                  
 
 
 
 
Figure 1.4: The structure of fexinidazole, a potential drug candidate for the treatment of 
sleeping sickness.  
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The in vivo activity of fexinidazole against sleeping sickness trypanosomes was substantiated 
in 1983 but the development of this promising compound was never pursued at the time.
1
  
Fexinidazole is administered orally and is quickly metabolised to give two active metabolites 
with equivalent activities to that of the parent compound. If it passes the clinical trials, 
fexinidazole has the potential to become a novel, oral and short-course treatment for both 
stage 1 and stage 2 of sleeping sickness and supersede the old and problematic therapies 
currently in use.
1,17,18
 Fexinidazole, therefore, has the potential to revolutionise the treatment 
of sleeping sickness. It will also reduce the cost of treatment in the resource-constrained 
settings affected by the disease, as doing away with intravenously administered drugs will 
lower the costs. The need for skilled professionals and hospitalisation for up to two weeks 
will be reduced with the introduction of an orally administered drug; which are necessary for 
the current therapies as they are injectables, difficult to administer and cause severe adverse 
effects that need to be monitored.
1
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Information gathered from Simarro et al.
7
, Fairlamb
20
, Yun et al.
19
, Torreele et al.
1
 and World 
Health Organization
6
. 
 
                                                                                      CHAPTER I: LITERATURE REVIEW    
 
14 
 
1.10 NAPHTHOQUINONES 
 1.10.1 Naphthoquinones as potential drug candidates 
 In the year 2000 at a summit of the United Nations, eight millennium development goals 
(MDGs) were set to be achieved by 2015. MDG 6 states “to combat HIV/AIDS, malaria & 
other diseases”. With just under 2 years to go before the end of 2015,  malaria and HAT are 
still thriving in developing countries.
24
 The drugs currently used for the treatment of HAT 
have fatal side effects, are limited in range and are in short supply. The drugs are also old and 
those used to treat late stages of the disease are very difficult to administer.
1
 The 
aforementioned challenges call for research and development into this neglected disease in 
order to come up with new, safe and easy-to-use medicines. 
This study focuses on a class of compounds called naphthoquinones which have been 
reported to possess a variety of biological activities, including anti-parasitic, anti-fungal, anti-
cancer, anti-bacterial, anti-inflammatory, anti-molluscicidal and anti-viral activities.
25-27
 A 
wide spectrum of activities exhibited by naphthoquinones are believed to be due to their 
ability to generate free radicals. Natural and synthetic naphthoquinones have the potential to 
accept one and/or two electron(s) to form radical anion or dianion species.
26
 Some studies 
have gone to greater heights to demonstrate the production of free radicals or reactive oxygen 
species (ROS) by naphthoquinones derivatives at mitochondrial level. 
28
 A study conducted 
by Pieretti and colleagues demonstrated the capability of 2-phenoxy-1,4-naphthoquinone to 
generate ROS. This was proven by measuring radical formation during respiration in a 
mitochondrial fraction of T.brucei both in the presence and absence of 2-phenoxy-1,4-
naphthoquinone. Further experiments carried out during this study using trypanosomal 
isolated mitochondria also demonstrated that 2-phenoxy-1,4-naphthoquinone was able to 
interfere with the respiratory chain through production of ROS.
28
 Other researchers have used 
electrochemical studies whereby cyclic voltammetry measurements, in aprotic media, were 
done to demonstrate the potential of naphthoquinones to accept electrons and form free 
radicals.
29,30
 A cyclic voltammogram of 2,3-dichloro-1,4-naphthoquinone (starting material 
of this study) obtained by Sayil and colleagues
30
 reviewed two reversible monoelectric 
waves. The first reversible reduction wave was attributed to the formation of a semiquinone 
anion radical (Q
-
): 
                                     Q + e
- Q
.-
(reversible)
                              (1) 
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The second wave was attributed to the reduction of the semiquinone anion radical to a 
dianion (Q
2-
): 
                                    Q
.-
+ e
- Q2
-
(quasi-reversible)
                  (2) 
 Numerous studies have reported this typical behavior of the reduction of naphthoquinones in 
aprotic conditions.
29-31
 Formation of ROS and the redox potential of synthetic as well as 
natural naphthoquinones are believed to cause oxidative stress, giving this class of 
compounds its wide spectrum of biological activities.
28,32
 
 
1.10.2 Naphthoquinone derivatives on the market 
Atovaquone is a 1,4-naphthoquinone derivative currently on the market and is registered for 
the prevention of malaria, treatment of Pneumocystis pneumonia and toxoplasmosis. 
Atovaquone is a derivative of lapachol (Figure 1.6), a naturally occurring 1,4-
naphthoquinone.
33
  Other marketed 1,4-naphthoquinones are K vitamins, phylloquinone and 
menaquinone (Figure 1.7). Phylloquinone, also known as vitamin K1, is used as an antidote 
for treating an overdose of warfarin, a vitamin K antagonist.
21
  
                                               
O
O
OH
Cl
H
Ha
O
O
OH
b
Figure 1.6: a) Structure of atovaquone, a 1,4-naphthoquinone compound and derivative of 
lapachol, currently on the market for prevention of malaria. b) Structure of lapachol, a 
naturally occurring 1,4-naphthoquinone derivative explored for various activities including 
anti-tumuor activity.
33
 Structures adapted and re-drawn from Epifano et al.
33
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Figure 1.7: a) Structure of vitamin K1, composed of a 1,4-naphthoquinone ring and an 
aliphatic side chain b) Structure of vitamin K2, composed of 1,4-naphthoquionone backbone 
and a side chain with isoprenoid units which can vary with four units being common.  
 
1.10.3 Previous studies of anti-trypanosomal assays of 1,4-naphthoquinone derivatives 
Extensive studies have been conducted on the synthesis and analysis of biological activities 
of naphthoquinone derivatives but a few of them have focused on their potential anti-
trypanosomal activity.   
Pieretti et al.
28
 carried out a structure-activity relationship study of 1,4-naphthoquinones 
shown in Figure 1.8 below. In this study, different positions of hydroxyl groups on the 
naphthoquinone backbone and the presence of an amino substituent on the phenoxy moiety 
were investigated with respect to trypanosomal activity. The study revealed that shifting of 
the   hydroxyl group from the eighth to the fifth position on the naphthoquinone backbone 
reduced anti-trypanosomal activity by 5-fold and the addition of an amino group on the 
phenoxy moiety reduced the activity by 7-fold (Figure 1.8).
28
 
Furthermore, the study pursued 2-(4-aminophenoxy)-1,4-naphthoquine (Figure 1.8) to 
determine its mechanism of action against T.b. rhodesiense. The study concluded that 
naphthoquinones (Figure 1.8) exert their anti-trypanosomal activity, through a multi-target 
mechanism, including interference of parasite mitochondrial respiratory chain as a result of 
the generation of reactive oxygen species by the naphthoquinones.
28
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Figure 1.8: 1,4-naphthoquinone derivatives with their respective trypanosomal activities 
against T.b. rhodesiense parasites as reported by Pieretti et al (2012).
28
  
 
1.11 AIMS AND OBJECTIVES  
There has been an increasing interest in the development of new naphthoquinone derivatives 
in which the 1,4-naphthoquinone pharmacophore is retained. Bio-assaying these naphtho-
quinone derivatives for various activities in search of new hit candidates, which can further 
progress to the hit-to-lead and lead optimisation stages of drug discovery, is on the rise.  
The research questions for this study were whether the electronegativity of substituents, the 
position of substituents (para, ortho and meta), linkages and either monosubstitution or 
disubstitution of 1,4-naphthoquinone derivatives have an effect on anti-trypanosomal activity. 
In light of the above, the aims and objectives of this study were: 
 To synthesise derivatives of 2,3-dichloro-1,4-naphthoquinone: 
o With thioether (-S-), ether (-O-) and amino (-NH-) linkages by coupling the 
naphthoquinone with three types of nucleophiles namely thiols, phenols and 
anilines. 
o From various nucleophiles with electronegative halogen substituents and 
electron-donating methyl substituents on para, meta and ortho positions. 
o Which are monosubstituted and disubstituted.   
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 To screen the synthesised naphthoquinone derivatives against T.brucei. 
 To conduct structure-activity relationship (SAR) and quantitative structure-activity 
relationship (QSAR) studies to determine which structural features or functional 
group substituents of the naphthoquinone derivatives contribute or take away from 
the desired anti-trypanosomal activity. 
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 CHAPTER II: METHODOLOGY 
 
2.1 INTRODUCTION 
Synthesis of 1,4-naphthoquinone derivatives from aniline, phenol and thiophenol nucleophiles 
will be discussed in this chapter. The synthetic procedures were adopted and modified from 
available literature.
1,2
 While various methods have been proposed for the synthesis of 
naphthoquinone derivatives, a single-step reaction using ethanolic solutions was used for this 
project. Other methods put forward in literature for the synthesis of naphthoquinone derivatives 
include:  
 ‘On-water’/‘in-water’ reactions which make use of aqueous micellar solutions of sodium 
lauryl sulphate with micelles acting as micro-reactors or catalysts
3,4
 
 Buchwald-Hartwig cross-coupling reactions which make use of transition metals such as 
palladium for catalysis
5,6
 
 One-pot laccase enzyme catalyzed method7 
 
2.2 EXPERIMENTAL  
2.2.1 Equipment and materials 
Reactants and reagents were obtained from Sigma-Aldrich
®
 (South Africa) and Saarchem (Pty) 
Ltd (South Africa). Organic solvents (methanol, n-hexane and ethyl acetate) used for chemical 
synthesis and thin layer chromatographic analysis were LiChrosolv
®
 liquid chromatography 
grades from Merck KGaA (Germany). The chloroform used for recrystallisation was a 
chemically pure grade from Minema Chemicals (Pty) Ltd (South Africa). Deuterated chloroform 
for the NMR analysis and the absolute ethanol for chemical synthesis were obtained from Merck 
KGaA (Germany). No further purification of any of the organic solvents was carried out. 
Silicone oil for an oil bath was obtained for Sigma-Aldrich
®
 (USA).  
Chemical reactions were carried out in round bottom flasks that were submerged in a silicone oil 
bath placed on top of a Fried Electric (Israel) hot plate/magnetic stirrer. A 76 mm immersion 
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thermometer was used to alter the temperature of the silicone oil bath. Thin layer 
chromatography (TLC) was carried out on TLC silica gel 60F254 aluminium plates from Merck 
KGaA (Germany) and, the TLC plates were visualised using Syngene 254, 365 nm UV lamb. 
Melting point determinations were carried out using a Stuart
®
 SMP30 digital and advanced 
melting point apparatus (United Kingdom). Synthesised products were stored in size 6 glass vials 
from Lasec (South Africa).  
Nuclear magnetic resonance (NMR) spectra were recorded on a 600MHz Bruker 600 
UltraShield
TM
 spectrometer and 400MHz Bruker spectrometer in a chloroform-d1 (CDCl3) 
solution. Chemical shifts (δ) of the NMR spectra are reported in parts per million (ppm) with 
reference to tetramethylsilane (TMS). The coupling constants (J) of the NMR spectra are given 
in hertz (Hz). MestReNova was the chemical software used to view the processed NMR spectra 
as well as for integration, multiplicity and obtaining coupling constants.  
 A Finnigan LCQ mass spectrometer (ESI, APCI) was used to determine the molecular weight of 
the synthesised products. A dual system of high pressure liquid chromatography coupled to 
electro-spray ionisation mass spectrometry (HPLC-ESI-MS) was utilised. The source of LCQ-
MS detector for the mass spectrometry analysis was ESI and it was in the positive ion mode. 
Samples were dissolved in ethyl acetate and protonation of the analytes was performed in order 
to produce ‘electron-spray active’ species. Protonation of the samples was carried out by spiking 
the sample solution with one or two drops of acid.  
Infrared spectra of the N-substituted 1,4-naphthoquinones derivatives (compounds 1a-1f) were 
recorded on a PerkinElmer Spectrum 100 FT-IR spectrometer with a potassium bromide (KBr) 
pellet. 
   
  
 
  
 
                                                                                                    CHAPTER II: METHODOLOGY 
 
25 
 
 2.2.2 Synthesis of 1,4-naphthoquinone derivatives 
2.2.2.1 Coupling with anilines  
 
Synthesis of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 1a 
                   
                         
6
7
8
5
1
2
34
NH
Cl
O
O
1'
6'
5'
4'
3'
2'
1a  
To a suspension of 2,3-dichloro-1,4-naphthoquinone (2.27 g; 10 mmol) in absolute ethanol (50 
mL) was pipetted aniline (0.9 mL; 12 mmol). The reaction mixture was stirred and heated in a 
silicone oil bath, maintained at 80 °C for 6 hours.  The reaction mixture was cooled to room 
temperature and the crude product was collected on a Büchner funnel by vacuum filtration. The 
residue was recrystallised from chloroform and methanol (3:1) to afford 2-chloro-3-
(phenylamino)-1,4-naphthoquinone 1a as  a maroon, needle-like solid (1.6392 g; 57.8%); mp 
213 °C (lit.
2
 218-221 °C); 
1
H NMR (600 MHz, CDCl3): δ 8.19 (d, J = 7.7 Hz, 1H, H8), 8.12 (d, J 
= 7.6 Hz, 1H, H5 ), 7.77 (td, J = 7.6, 1.1 Hz, 1H, H7), 7.70 – 7.68 (m, 2H, H6 overlapping with 
NH), 7.35 (t, J = 7.9 Hz, 2H, H3’ and H5’), 7.22 (t, J = 7.4 Hz, 1H, H4’), 7.09 (d, J = 7.9 Hz, 
2H, H2’ and H6’); IR (KBr, cm-1): 3233.81 (-NH), 1673.86 and 1636.37 (-C=O of the quinone); 
HPLC-ESI-MS (m/z): [M+3H]
+ 
(286.53).  
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Synthesis of 2-chloro-3-(4-chlorophenylamino)-1,4-naphthoquinone 1b 
              
                          
6
7
8
5
1 2
34
O
O
NH
Cl
1'
6'
5'
4'
3'
2'
Cl
1b  
   
To a solution of 4-chloroaniline (1.2757 g; 10 mmol) in absolute ethanol (50 mL) was added 2,3-
dichloro-1,4-naphthoquinone (2.27 g; 10 mmol). The reaction mixture was stirred and heated in a 
silicone oil bath, maintained at 80 °C for 6 hours.  The reaction mixture was then cooled to room 
temperature and the crude product was collected on a Büchner funnel by vacuum filtration. The 
residue was recrystallised from chloroform and methanol (3:1) and then further recrystallised 
from methanol to afford 2-chloro-3-(4-chlorophenylamino)-1,4-naphthoquinone 1b   as  a 
maroon solid (2.2236 g; 69.9%); mp 265-269 °C (lit.
2
 263-265 °C); 
1
H NMR (600 MHz, CDCl3) 
δ 8.20 (d, 1H, H8), 8.12 (d, 1H, H5), 7.79 (t, 1H, H7), 7.71 (t, 1H, H6), 7.62 (s, 1H, -NH), 7.32 
(d, J = 7.2 Hz, 2H, H3’ and H5’), 7.01 (d, J = 7.2 Hz, 2H, H2’ and H6’); IR (KBr, cm-1): 3225.94 
(-NH), 1673.71 and 1638.80 (-C=O of the quinone); HPLC-ESI-MS (m/z): [M+3H]
+ 
(320.67). 
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Synthesis of 2-chloro-3-(4-bromophenylamino)-1,4-naphthoquinone 1c 
                 
              
6
7
8
5
1 2
34
NH
Cl
O
O
1'
6'
5'
4'
3'
2'
Br
1c  
 
To a solution of 4-bromoaniline (0.8601 g; 5 mmol) in absolute ethanol (25 mL) was added 2,3-
dichloro-1,4-naphthoquinone (1.135 g; 5 mmol). The reaction mixture was stirred and heated in a 
silicone oil bath which was maintained at 80 °C for 6 hours.  The reaction mixture was cooled to 
room temperature and the crude product was collected on a Büchner funnel by vacuum filtration. 
The residue was recrystallised from chloroform and methanol (3:1), twice, to afford 2-chloro-3-
(4-bromophenylamino)-1,4-naphthoquinone as  a maroon solid (1.1808 g; 65.1%); mp 276.1-
277.9°C (lit.
2
 237-239 °C);  
1
H NMR (600 MHz, CDCl3) δ 8.20 (d, J = 7.7 Hz, 1H, H8), 8.13 (d, 
J = 7.5 Hz, 1H, H5), 7.79 (t, J = 7.3 Hz, 1H, H7), 7.71 (t, J = 7.6 Hz, 1H, H6), 7.60 (s, 1H, NH), 
7.47 (d, J = 8.5 Hz, 2H, H3’ and H5’), 6.95 (d, J = 8.4 Hz, 2H, H2’ and H6’); IR (KBr, cm-1): 
3235.54 (-NH),   and 1673.80 and 1635.52 (-C=O of the quinone); HPLC-ESI-MS (m/z): 
[M+2H]
+ 
(364.73). 
 
 
 
 
 
 
                                                                                                    CHAPTER II: METHODOLOGY 
 
28 
 
Synthesis of 2-chloro-3-(p-tolylamino)-1,4-naphthoquinone 1d 
 
                           
6
7
8
5
2
34
O
O
NH
Cl
1'
6'
5'
4'
3'
2'
CH3
1d
1
 
 
To a solution of p-toluidine, also known as 4-methylaniline, (1.0715 g; 10 mmol) in absolute 
ethanol (50 mL), was added 2,3-dichloro-1,4-naphthoquinone (2.27 g; 10 mmol). The reaction 
mixture was stirred and heated in a silicone oil bath, maintained at 80 °C for 6 hours.  The 
reaction mixture was cooled to room temperature and the crude product was collected on a 
Büchner funnel by vacuum filtration. The residue was recrystallised from chloroform and 
methanol (3:1), twice, to afford 2-chloro-3-(p-tolylamino)-1,4-naphthoquinone 1d  as  a maroon, 
needle-shaped solid (1.632 g; 54.8%); mp 193.3-196.7 °C (lit.
2
 184-186 °C); 
1
H NMR (400 
MHz, CDCl3) δ 8.18 (d, J = 7.7 Hz, 1H, H8), 8.10 (d, J = 7.5 Hz, 1H, H5), 7.78 – 7.74 (m, 1H, 
H7), 7.69 – 7.65 (m, 2H, H6 overlapping with NH), 7.15 (d, J = 8.0 Hz, 2H, H3’ and H5’), 6.98 
(d, J = 8.1 Hz, 2H, H2’ and H6’), 2.36 (s, 3H, -CH3); IR (KBr, cm
-1
): 3219.19 (-NH), 1674.93 
and 1631.41 (-C=O of the quinone); HPLC-ESI-MS (m/z): [M+3H]
+ 
(300.60). 
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Synthesis of 2-chloro-3-(4-(trifluoromethyl)phenylamino)-1,4-naphthoquinone 1e 
               
                     
6
7
8
5
1 2
34
O
O
NH
Cl
1'
6'
5'
4'
3'
2'
CF3
1e  
 
To a solution of 4-(trifluoromethyl)aniline (0.5mL; 4 mmol) in absolute ethanol (20 mL), was 
added triethylamine base (0.15 mL; 1 mmol) and then 2,3-dichloro-1,4-naphthoquinone (0.908 g; 
4 mmol). The reaction mixture was stirred and heated in a silicone oil bath which was 
maintained between 80-100 °C for 10 hours.  The reaction mixture was then cooled to room 
temperature and the crude product was collected on a Büchner funnel by vacuum filtration. The 
residue was recrystallised from chloroform and methanol (3:1) to afford 2-chloro-3-(4-
(trifluoromethyl)phenylamino)-1,4-naphthoquinone 1e as orange, needle-shaped crystals (0.4925 
g; 35.0%); mp 249.4-251.8 °C; 
1
H NMR (400 MHz, CDCl3) δ 8.21 (d, J = 7.6 Hz, 1H, H8), 8.15 
(d, J = 7.5 Hz, 1H, H5), 7.80 (t, J = 7.5 Hz, 1H, H7), 7.73 (t, J = 7.6 Hz, 1H, H6), 7.68 (s, 1H, 
NH), 7.61 (d, J = 8.2 Hz, 2H, H3’ and H5’), 7.12 (d, J = 8.1 Hz, 2H, H2’ and H6’); IR (KBr, cm-
1
): 3243.81 (-NH), 1673.30 and 1638.98 (-C=O of the quinone); HPLC-ESI-MS (m/z): [M+1H]
+ 
(352.73 ). 
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Synthesis of 2-chloro-3-(o-tolylamino)-1,4-naphthoquinone 1f 
 
                        
6
7
8
5
1 2
34
O
O
NH
Cl
1'
6'
5'
4'
3'
2'
CH3
1f  
 
 
To a solution of 2-methylaniline, also known as o-toluidine, (1 mL; 10 mmol) in absolute ethanol 
(50 mL), was added 2,3-dichloro-1,4-naphthoquinone (2.27 g; 10 mmol). The reaction mixture 
was stirred and heated in a silicone oil bath, maintained at 80 °C for 8 hours.  The reaction 
mixture was cooled to room temperature and the crude product was collected on a Büchner 
funnel by vacuum filtration. The residue was recrystallised from chloroform and methanol (3:1) 
to afford 2-chloro-3-(o-tolylamino)-1,4-naphthoquinone 1f as  a maroon powder (0.8441 g; 
28.4%); mp 163.3-165.1 °C; 
1
H NMR (600 MHz, CDCl3) δ 8.19 (d, J = 7.7 Hz, 1H, H8), 8.12 (d, 
J = 7.6 Hz, 1H, H5), 7.77 (t, J = 7.5 Hz, 1H, H7), 7.69 (t, J = 7.5 Hz, 1H, H6), 7.47 (s, 1H, -NH), 
7.25 – 7.21 (m, 1H, phenyl-H), 7.21 – 7.17 (m, 2H, 2x phenyl-H), 7.04 (dd, J = 8.8, 4.2 Hz, 1H, 
phenyl-H), 2.30 (s, 3H, -CH3); IR (KBr, cm
-1
): 3243.81 (-NH), 1673.30 and 1638.98  (-C=O of 
the quinone); HPLC-ESI-MS (m/z): [M+1H]
+ 
(298.60 ). 
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Synthesis of 2-chloro-3-(3-methoxyphenylamino)-1,4-naphthoquinone 1g 
  
                       
6
7
8
5
1 2
34
O
O
NH
Cl
1'
6'
5'
4'
3'
2'
O
CH3
1g  
 
To a solution of 3-methoxyaniline, also called m-anisidine, (0.6 mL; 5 mmol) in absolute ethanol 
(25 mL) was added 2,3-dichloro-1,4-naphthoquinone (1.135 g; 5 mmol). The reaction mixture 
was stirred and heated in a silicone oil bath which was maintained at 80 °C for 6 hours.  The 
reaction mixture was then cooled to room temperature and the crude product was collected on a 
Büchner funnel by vacuum filtration. The residue was recrystallised from methanol, twice, and 
then in hexane to afford 2-chloro-3-(3-methoxyphenylamino)-1,4-naphthoquinone 1g   as  a 
maroon solid (0.8922 g; 56.9%); mp 147.4-149.7 °C; 
1
H NMR (600 MHz, CDCl3) δ 8.19 (dd, J 
= 8.4, 3.5 Hz, 1H, H8), 8.11 (d, J = 7.6 Hz, 1H, H5), 7.76 (t, J = 7.3 Hz, 1H, H7), 7.69 (t, J = 7.4 
Hz, 1H, H6), 7.66 (s, 1H, -NH), 7.24 (t, J = 8.1 Hz, 1H, H5’), 6.76 (dd, J = 8.3, 2.3 Hz, 1H, 
H6’), 6.68 (dd, J = 7.9, 1.3 Hz, 1H, H4’), 6.61 (s, 1H, H2’), 3.81 (s, 3H, -OCH3); IR (KBr,cm
-1
): 
3219.32 (-NH), 1673.67 and 1643.68 (-C=O of the quinone); HPLC-ESI-MS (m/z): [M+3H]
+ 
(316.73).  
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Synthesis of 2-chloro-3-(m-tolylamino)-1,4-naphthoquinone 1h 
 
                              
6
7
8
5
1
2
34
O
O
NH
Cl
1'
6'
5'
4'
3'
2'
CH3
1h  
 
To a solution of 3-methylaniline, also known as m-toluidine, (0.55 mL; 5 mmol) in absolute 
ethanol (25 mL) was added 2,3-dichloro-1,4-naphthoquinone (1.135 g; 5 mmol). The reaction 
mixture was stirred and heated in a silicone oil bath, maintained at 80 °C for 9 hours.  The 
reaction mixture was then cooled to room temperature and the crude product was collected on a 
Büchner funnel by vacuum filtration. The residue was recrystallised from methanol, twice, and 
then from hexane to afford 2-chloro-3-(m-tolylamino)-1,4-naphthoquinone 1h   as  a maroon 
solid (1.0763 g; 72.3%); mp 177.2-181.5 °C; 
1
H NMR (600 MHz, CDCl3) δ 8.19 (d, J = 7.7 Hz, 
1H, H8), 8.12 (d, J = 7.6 Hz, 1H, H5), 7.77 (t, J = 7.5 Hz, 1H, H7), 7.69 (t, J = 7.6 Hz, 1H, H6), 
7.66 (s, 1H, -NH), 7.23 (t, J = 8.0 Hz, 1H, H5’), 7.03 (d, J = 7.6 Hz, 1H, H4’/H6’), 6.89 (d, J = 
5.0 Hz, 1H, H6’/H4’), 6.88 (s, 1H, H2’), 2.36 (s, 3H, -CH3); IR (KBr, cm
-1
): 3226.17  (-NH), 
1676.83 and 1630.92 (-C=O of the quinone); HPLC-ESI-MS (m/z): [M+3H]
+ 
(300.73 ). 
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             2.2.2.2 Coupling with phenols 
 
Synthesis of 2-chloro-3-phenoxy-1,4-naphthoquinone 2a 
 
                        
6
7
8
5
1
2
34
O
O
O
Cl
1'
6'
5'
4'
3'
2'
2a  
 
To a solution of phenol (1.8822 g; 20 mmol) in absolute ethanol (40 mL) was added 
triethylamine base (0.45 mL; 3mmol) and then 2,3-dichloro-1,4-naphthoquinone (2.27 g; 10 
mmol). The reaction mixture was stirred and heated in a silicone oil bath, maintained at 80 °C for 
6 hours.  The reaction mixture was then cooled to room temperature and the precipitated crude 
product was collected on a Büchner funnel by vacuum filtration. The residue was recrystallised 
from hexane to afford 2-chloro-3-phenoxy-1,4-naphthoquinone 2a as  a yellow, fluffy solid 
(1.596 g; 56.1%); mp 133.1-135.0 °C (lit.
8
 138-139 °C); 
1
H NMR (600 MHz, CDCl3) δ 8.22 (dd, 
J = 7.5, 1.2 Hz, 1H, H8), 8.06 (dd, J = 7.5, 1.2 Hz, 1H, H5), 7.83 – 7.74 (m, 2H, H6 and H7), 
7.34 (t, J = 7.8 Hz, 2H, H3’ and H5’), 7.15 (t, J = 7.4 Hz, 1H, H4’), 7.02 (d, J = 7.8 Hz, 2H, H2’ 
and H6’); HPLC-ESI-MS (m/z): [M+2H]+ (286.67 ). 
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Synthesis of 2-chloro-3-(2-chlorophenoxy)-1,4-naphthoquinone 2b 
 
                               2b
6
7
8
5
1
2
34
O
O
O
Cl
1'
6'
5'
4'
3'
2'
Cl
 
 
To a solution of 2-chlorophenol (1 mL; 10 mmol) in absolute ethanol (25 mL) was added 
triethylamine base (0.45 mL; 3 mmol) and then 2,3-dichloro-1,4-naphthoquinone (1.135 g; 5 
mmol). The reaction mixture was stirred and heated in a silicone oil bath, maintained at 80 °C for 
24 hours.  The reaction mixture was gravity filtered whilst hot, so as to remove the orange solid 
sediment at the bottom of the round bottomed flask. The orange sediment was removed from the 
flask by dissolving it in ethyl acetate and air dried in a fume hood to give orange, shinny, needle-
shaped crystals. The needle-shaped crystals were obtained without purification to afford 2-
chloro-3-(2-chlorophenoxy)-1,4-naphthoquinone 2b.  The hot filtrate from the gravity filtration 
of the reaction mixture was then cooled to room temperature and the precipitated crude product 
was collected on a Büchner funnel by vacuum filtration. The crude product was recrystallised 
from methanol and then from hexane to 2-chloro-3-(2-chlorophenoxy)-1,4-naphthoquinone 2b as 
a dark yellow, amorphous powder. The crystals and amorphous powder showed similar 
1
H NMR 
spectra and Rf value of 0.72. Total yield (0.6512 g; 40.8%); mp of orange crystals of 2b was 
178.3-181.3 °C; mp of the dark yellow, amorphous powder of 2b was 172.1-175.7°C; 
1
H NMR 
(600 MHz, CDCl3) δ 8.21 (dd, J = 7.6, 1.3 Hz, 1H, H8), 8.03 (dd, J = 7.6, 1.3 Hz, 1H, H5), 7.82 
– 7.73 (m, 2H, H6 and H7), 7.45 (dd, J = 8.0, 1.6 Hz, 1H, H3’), 7.22(td, J = 7.8, 1.4 Hz, 1H, 
H5’), 7.12 (td, J = 7.8, 1.4 Hz, 1H, H4’), 6.98 (dd, J = 8.1, 1.4 Hz, 1H, H6’); HPLC-ESI-MS 
(m/z): [M+1H]
+ 
(320.92 ). 
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Synthesis of 2-chloro-3-(2-chloro-4-methylphenoxy)-1,4-naphthoquinone 2c 
 
 
                                   
6
7
8
5
1 2
34
O
O
Cl
1'
6'
5'
4'
3'
2'
Cl
CH
3
O
2c  
 
To a solution of 2-chloro-4-methylphenol (1.18 ml; 10 mmol) in absolute ethanol (25 ml) was 
added triethylamine base (0.45 ml; 3 mmol) and then 2,3-dichloro-1,4-naphthoquinone (1.135 g; 
5 mmol). The reaction mixture was stirred and heated in a silicone oil bath, maintained at 80 °C 
for 24 hours.  The reaction mixture was then cooled to room temperature and the precipitated 
crude was collected on a Büchner funnel by vacuum filtration. The residue was recrystallised 
from hexane, and then further from methanol, to afford 2-chloro-3-(2-chloro-4-methylphenoxy)-
1,4-naphthoquinone 2c as orange, needle-shaped crystals (0.8649 g; 51.9%); mp 143.9-146.2 °C; 
1
H NMR (400 MHz, CDCl3) δ 8.20 (dd, J = 7.5, 1.3 Hz, 1H, H8), 8.02 (dd, J = 7.4, 1.3 Hz, 1H, 
H5), 7.84 – 7.71 (m, 2H, H6 and H7), 7.25 ( s, 1H, H3’), 7.01 (dd, J = 8.3, 1.4 Hz, 1H, H5’/H6’), 
6.89 (d, J = 8.3 Hz, 1H, H6’/H5’), 2.33 (s, 3H, -CH3); HPLC-ESI-MS (m/z): [M+1H]
+ 
(334.88 ). 
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Synthesis of 2-chloro-3-(3,5-dimethylphenoxy)-1,4-naphthoquinone 2d 
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CH3
CH3
2d  
 
To a solution of 3,5-dimethylphenol (1.2216 g; 10 mmol) in absolute ethanol (25 mL) was added 
triethylamine base (0.45 mL; 3 mmol) and then 2,3-dichloro-1,4-naphthoquinone (1.135 g; 5 
mmol). The reaction mixture was stirred and heated in a silicone oil bath, maintained at 80 °C for 
6 hours.  The reaction mixture was then cooled to room temperature and the precipitated crude 
product was collected on a Büchner funnel by vacuum filtration. The residue was recrystallised 
from hexane and further from methanol to afford 2-chloro-3-(3,5-dimethylphenoxy)-1,4-
naphthoquinone 2d as a dark yellow, needle-shaped, fluffy solid (0.8383 g; 53.6%); mp 155.9-
157.4 °C (lit
3
 no mention of the melting point); 
1
H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 6.8 
Hz, 1H, H8), 8.12 – 8.00 (m, 1H, H5), 7.87 – 7.70 (m, 2H, H6 and H7), 6.77 (s, 1H, H4’), 6.62 
(s, 2H, H2’ and H6’), 2.29 (s, 6H, 2x -CH3); HPLC-ESI-MS (m/z): [M]
+ 
(313.06).  
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Synthesis of 2-chloro-3-(4-chlorophenoxy)-1,4-naphthoquinone 2e 
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To a solution of 4-chlorophenol (1.2856 g; 10 mmol) in absolute ethanol (25 mL) was added 
triethylamine base (0.45 mL; 3 mmol) and then 2,3-dichloro-1,4-naphthoquinone (1.135 g; 5 
mmol). The reaction mixture was stirred and heated in a silicone oil bath, maintained at 80 °C for 
6 hours.  The reaction mixture was then cooled to room temperature and the precipitated crude 
product was collected on a Büchner funnel by vacuum filtration. The residue was recrystallised 
from hexane and then further from methanol to afford 2-chloro-3-(4-chlorophenoxy)-1,4-
naphthoquinone 2e as a yellow powder;  (0.6834 g; 42.8%); mp 129.7-132.1 °C; 
1
H NMR (400 
MHz, CDCl3) δ 8.22 (dd, J = 7.3, 1.5 Hz, 1H, H8), 8.06 (dd, J = 7.2, 1.5 Hz, 1H, H5), 7.85 – 
7.75 (m, 2H, H6 and H7), 7.30 (d, J = 8.9 Hz, 2H, H3’ and H5’), 6.96 (d, J = 8.9 Hz, 2H, H2’ 
and H6’). 
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2.2.2.3 Coupling with thiophenols 
Synthesis of 2,3-bis(phenylthio)-1,4-naphthoquinone 3a 
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To a solution of thiophenol (2 mL; 20 mmol) in absolute ethanol (50 mL) was added 2,3-
dichloro-1,4-naphthoquinone (2.27 g; 10 mmol). The reaction mixture was stirred and heated 
under in a silicone oil bath, maintained at 40 °C for 6 hours.  The reaction mixture was cooled to 
room temperature and left in a fume hood overnight to get rid of the sulphur-like smell. The 
precipitated crude product was collected on a Büchner funnel by vacuum filtration. The residue 
was recrystallised from a mixture of hexane and methanol to afford 2,3-bis(phenylthio)-1,4-
naphthoquinone 3a as dark orange, needle-shaped crystals;  (3.2677 g; 87.3%); mp 150.8-152.8 
°C (lit
1
 150 °C) ;
1
H NMR (600 MHz, CDCl3) δ 8.00 – 7.96 (m, 2H, H5 and H8), 7.69 – 7.65 (m, 
2H, H6 and H7), 7.39 – 7.37 (m, 4H, 2x H2’ and H6’), 7.32 – 7.28 (m, 6H, 2x H3’, H4’ and 
H5’); HPLC-ESI-MS (m/z): [M]+ (374.95). 
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Synthesis of 2,3-bis(4-chlorophenylthio)-1,4-naphthoquinone 3b 
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To a solution of 4-chlorothiophenol (0.7231 g; 5 mmol) in absolute ethanol (25 mL) was added 
2,3-dichloro-1,4-naphthoquinone (1.135 g; 5 mmol). The reaction mixture was stirred and heated 
in a silicone oil bath, maintained at 80 °C for 6 hours.  The reaction mixture was cooled to room 
temperature and the precipitated crude product was collected on a Büchner funnel by vacuum 
filtration. The residue was first recrystallised from methanol and then further from a 
methanol/hexane (3:2) mixture to afford 2,3-bis(4-chlorophenylthio)-1,4-naphthoquinone 3b as a 
mud brown, fluffy solid;  (1.1155 g; 50.3%); mp 178.6-179.9 °C; 
1
H NMR (600 MHz, CDCl3) δ 
8.00 – 7.96 (m, 2H, H5 and H8), 7.72 – 7.67 (m, 2H, H6 and H7), 7.32 (d, J = 8.5 Hz, 4H, 2x 
H3’ and H5’), 7.28 (d, J = 8.5 Hz, 4H, 2x H2’ and H6’). 
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Synthesis of 2,3-bis(4-bromophenylthio)-1,4-naphthoquinone 3c 
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To a solution of 4-bromothiophenol (0.9454 g; 5 mmol) in absolute ethanol (25 mL) was added 
triethylamine base (1 mmol; 0.15 mL) and 2,3-dichloro-1,4-naphthoquinone (0.5675 g; 2.5 
mmol).  The reaction mixture was stirred and heated in a silicone oil bath, maintained at 80 °C 
for 6 hours. The product could be observed precipitating a few minutes after setting up the 
reaction. After 6 hours, the reaction mixture was cooled to room temperature and the precipitated 
crude product was collected on a Büchner funnel by vacuum filtration. The residue was first 
recrystallised from hexane and then from methanol to afford 2,3-bis(4-bromophenylthio)-1,4-
naphthoquinone 3c as a mud brown, fluffy solid;  (0.9970 g; 74.9%); mp 196.9-198.1 °C (lit
9
 207 
°C); 
1
H NMR (600 MHz, CDCl3) δ 8.00 – 7.96 (m, 2H, H5 and H8), 7.72 – 7.67 (m, 2H, H6 and 
H7), 7.43 (d, J = 8.4 Hz, 4H, 2x H3’ and H5’), 7.24 (d, J = 8.4 Hz, 4H, 2x H2’ and H6’). 
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Synthesis of 2,3-bis(p-tolylthio)-1,4-naphthoquinone 3d 
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To a solution of 4-methylthiophenol (0.621 g; 5 mmol) in absolute ethanol (25 mL) was added 
triethylamine base (2 mmol; 0.3mL) and 2,3-dichloro-1,4-naphthoquinone (0.5675 g; 2.5 mmol). 
The reaction mixture was stirred at room temperature for 12 hours.  The crude product was 
collected on a Büchner funnel by vacuum filtration. The residue was first recrystallised from 
hexane in a silicone oil bath set to 80 °C and a maroon product with traces of brown was 
obtained. Further recrystallisation from methanol afforded 2,3-bis(p-tolylthio)-1,4-
naphthoquinone 3d as a maroon powder; (0.5867 g; 58.3%); mp 174.8-176.8 °C (lit.
9
 169 °C); 
1
H NMR (600 MHz, CDCl3) δ 8.00 – 7.94 (m, 2H, H5 and H8), 7.69 – 7.62 (m, 2H, H6 and H7), 
7.29 (d, J = 8.1 Hz, 4H, 2x H2’ and H6’), 7.11 (d, J = 8.0 Hz, 4H, 2x H3’ and H5’), 2.34 (s, 6H, 
2x -CH3). 
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Synthesis of 2,3-bis(o-tolylthio)-1,4-naphthoquinone 3e 
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To a solution of 2-methylthiophenol (1.18 mL; 10mmol) in absolute ethanol (25 mL) was added 
triethylamine base (3 mmol; 0.45mL) and 2,3-dichloro-1,4-naphthoquinone (1.135 g; 5 mmol). 
The reaction mixture was stirred at room temperature for 24 hours.  The crude product was 
collected on a Büchner funnel by vacuum filtration. The residue was first recrystallised from 
hexane in a silicone oil bath set to 80 °C and then further recrystallisation from methanol to 
afford 2,3-bis(o-tolylthio)-1,4-naphthoquinone 3e as a yellow, fluffy solid;  (1.4732 g; 73.2%); 
mp 189.7-192.5 °C; 
1
H NMR (600 MHz, CDCl3) δ 7.98 – 7.92 (m, 2H, H5 and H8), 7.67 – 7.61 
(m, 2H, H6 and H7), 7.29 (d, J = 7.8 Hz, 2H, 2x H6’), 7.24 – 7.18 (m, 4H, 2x H4’ and H5’), 7.10 
(td, J = 8.3, 4.2 Hz, 2H, 2x H3’), 2.46 (s, 6H, 2x -CH3). 
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2.3 BIOLOGICAL ASSAY METHODS 
The biological assay was conducted by Raffaella Grimaldi of the Drug Discovery Unit at the 
University of Dundee in Dundee, Scotland using a similar procedure to that stipulated in one of 
their publication.
10
 The synthesised 1,4-naphthoquinone derivatives were given compound codes 
and packed into Eppendorf tubes for transportation. The compound codes used were denoted by 
my initials, the year and the page numbers of the laboratory note book. For example, compound 
1a was coded as CC13(3)-24 and chemical names were not revealed.  
 
2.3.1 Chemicals and materials used for biological assays 
Melarsoprol used as the reference standard was from Rhone-Poulenc (France), resazurin was 
from Sigma, the white bottom clear plates for T. brucei growth assays where obtained from 
Greiner and the echo plates from LabCyte.  
 
2.3.2 Trypanosome culture, preparation of compounds and growth assays 
Culturing of bloodstream-form T. b .brucei (strain 427) was carried out at 37ºC in the presence 
of 5% carbon dioxide in HMI9-medium.
10
 Cells were diluted to 2 x 10
4
 mL
-1
for 48 hour passages 
or diluted to 2 x 10
4
 mL
-1
for 72 hour passages. The cells were maintained in vented T75 flasks 
and the day before plating in 384-well plate, the cultures used for screening were split to 2 x 10
4
 
mL
-1
.  
To prepare the potency curves, 30 µL of compound in 10 mM in DMSO was dispensed into the 
384-well compound-holding plate manually. Assay plate preparations were carried out by 
transferring the serial dilutions to LabCyte Echo certified plates and 250 nL of each 
concentration was dispensed into white clear bottom 384-assays plates.
10
  
Standard growth assays were carried out by plating bloodstream form T. brucei, in fresh 
medium, into columns 1-22 of the 384-well assay plates using a Wellmate dispenser (50 
µL/well). Thereafter, incubation for 68 hour at 37 ºC in the presence of 5% carbon dioxide was 
carried out. At 0.05 mM final concentration, resazurin was added and the plates were incubated 
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for another 4 hours. Fluorescence was then measured using a Perkin Elmer Victor 3 plate-reader 
(excitation 528 nm, emission 590 nm). The determination of growth rates was conducted by 
harvesting cells every 24 hours from 384-well plates and they were counted in a CASY Counter 
(Roche).
10
   
 
2.3.3 Data analysis 
All data were the result of one independent measurement. The obtained monophasic dose-
response curves were fitted in Excel Add-in XL-fit (IDBS) following the 4 parametric equation 
equation: 
                                     y = A +       B-A 
 
where A = % inhibition at bottom, B = % inhibition at top, C = EC50, D = Hill slope, x = 
inhibition concentration and y = % inhibition.  
 
 
 
 
 
 
 
 
 
 
 
 
1+(C/x)
D
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CHAPTER III: RESULTS AND DISCUSSION OF THE SYNTHESIS  
 
3.1 NUCLEOPHILIC AROMATIC SUBSTITUTION REACTIONS 
 
O
O
Cl
Cl
Nu
O
Cl
O
O
O
Nu
Cl
Cl
Cl
Nu
Scheme 3.1: Proposed mechanism of reaction of nucleophilic aromatic substitution of 2,3-
dichloro-1,4-naphthoquinone with oxygen, nitrogen and sulphur nucleophiles, where Nu = 
nucleophile. The cycle is repeated in the case of disubstituted products to eliminate the second 
chlorine atom.  
 
Naphthoquinone derivatives with amino and thioether linkages have been described as a 
component of the molecular framework of numerous biologically potent chemical entities.
1,2
 
This became the foundation of exploring the synthesis of naphthoquinone derivatives by 
nucleophilic substitution with oxygen, sulphur and nitrogen nucleophiles in our study. 
Naphthoquinones are deemed to be a privileged class of compounds, as they have been reported 
to possess a variety of biological activities, including anti-parasitic, anti-fungal, anti-cancer, anti-
bacterial, anti-inflammatory, anti-molluscicidal and anti-viral activities.
3-5
 This is why an 
electrophile with the naphthoquinone backbone was chosen for the coupling reactions with 
nitrogen, oxygen and sulphur nucleophiles. Synthesis of naphthoquinone derivatives is usually 
achieved from 2,3-dichloro-1,4-naphthoquinone – a commercially available substrate which is 
relatively affordable.    
Various nitrogen, oxygen and sulphur nucleophiles with electron-withdrawing halogen 
substituents and electron-donating methyl substituents on para, meta and ortho positions were 
selected for coupling with the naphthoquinone (Scheme 3.2 and Table 3.1). The N-, S- and O-
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substituted 1,4-naphthoquinone derivatives had amino, thioether and ether linkages respectively. 
The purpose of using various nucleophiles was to investigate the effects of the structural features 
or functional group substituents of the naphthoquinone derivatives on biological activity. A 
structure-activity relationship study was conducted on the library of compounds to determine 
which structural features contribute or take away from the desired anti-trypanosomal activity. 
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                      where X= -O- , -S-, -NH- 
                                 Et3N = triethylamine, EtOH = ethanol 
                                 R1, R2, R3and R4 are defined in Table 3.1 below.  
 
Scheme 3.2: General reaction scheme of the coupling of 2,3-dichloro-1,4-naphthoquinone 1 with 
a nucleophile 2 to give either a monosubstituted product 3 or a disubstituted product 4 in a 
nucleophilic aromatic substitution reaction. Reaction conditions: absolute ethanol as the solvent, 
triethylamine as a base catalyst where applicable, temperatures between 25 °C and 80 °C.  
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Table 3.1: Nucleophiles that were reacted with 2,3-dichloro,1-4-naphthoquinone in absolute 
ethanol. 
 
NUCLEOPHILE 
 
X 
 
R1 
 
R2 
 
R3 
 
R4 
% 
Isolated 
yield  
 
1. Anilines  
      
a. Aniline -NH- -H -H -H -H 57.8 
b. 4-Chloroaniline  -NH- -Cl -H -H -H 69.9 
c. 4-Bromoaniline -NH- -Br -H -H -H 65.1 
d. 4-Methylaniline -NH- -CH3 -H -H -H 54.8 
e. 4-(Trifluoromethyl)aniline -NH- -CF3 -H -H -H 35.0 
f. 2-Methylaniline -NH- -H -CH3 -H -H 28.4 
g. 3-Methoxyaniline -NH- -H -H -H -OCH3 56.9 
h. 3-Methylaniline  -NH- -H -H -H -CH3 72.3 
    2-(Trifluoromethyl)aniline -NH- -H -CF3 -H -H 0 
       
2. Phenols       
a. Phenol -O- -H -H -H -H 56.1 
b. 2-Chlorophenol -O- -H -Cl -H -H 40.8 
c. 2-Chloro-4-methylphenol -O- -CH3 -Cl -H -H 51.9 
d. 3,5-Dimethylphenol -O- -H -H -CH3 -CH3 53.6 
e. 4-Chlorophenol -O- -Cl -H -H -H 42.8 
    Thymol -O- -H -C(CH3)2 -CH3 -H 0 
       
3. Thiophenols        
a. Thiophenol -S- -H -H -H -H 87.3 
b. 4-Chlorothiophenol -S- -Cl -H -H -H 50.3 
c. 4-Bromothiophenol -S- -Br -H -H -H 74.9 
d. 4-Methylthiophenol -S- -CH3 -H -H -H 58.3  
e. 2-Methylthiophenol -S- -H -CH3 -H -H 73.2 
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A number of reactions suffered from low yields as can be seen in Table 3.1. According to 
Furniss et al.(1989)
6
, “the success of a reagent is judged from the percentage yield, being 
excellent (>90%), very good (>80%), good (>70%), fair (>50%) and poor (<40%).” Based on 
this statement, the obtained isolated percentage yields ranged between poor, fair, good and very 
good. Various reasons may be postulated as to why such average yields were possible. First, it is 
likely the reactions may have reached their equilibrium before completion because un-reacted 
substrate (naphthoquinone) was isolated after the recrystallisation procedures. The 
naphthoquinone was either a soluble impurity that precipitated from the filtrate of the 
recrystallisation mixture, and the desired product as the residue. The naphthoquinone could also 
be an insoluble impurity that became the residue from filtration of the recrystallisation mixture 
with the desired product precipitating from the filtrate. The 
1
H NMR analysis of the un-reacted 
substrate confirmed that it was indeed the naphthoquinone.  
Second, protic solvents used such as ethanol may possibly slow down the rate of reaction by 
solvating the reactant nucleophile. The -NH2, -OH and -SH groups of the nucleophiles may form 
hydrogen bonds with the solvent (ethanol) molecules, which then cluster around the nucleophile 
and reduce its reactivity.
7,8
 A strongly solvated nucleophile must shed off some of the solvent 
molecules, so as to attack the carbon of the naphthoquinone bearing the chloride leaving group.
8
 
In addition, sulphur atoms are bigger than oxygen atoms and are not as strongly solvated in 
protic solvents such as ethanol. As a result, aryl thiols (R-SH) are stronger and more powerful 
nucleophiles than phenols (R-OH); Table 3.2.
8-10
 This was somewhat evinced by the higher 
yields obtained in reactions with thiol nucleophiles compared to the reactions involving phenols. 
Furthermore, greater reactivity of nucleophiles with large nucleophilic atoms may also be 
attributed to their greater polarisability. A bigger nucleophilic atom has the ability to donate a 
large electron density to the substrate compared to a smaller nucleophilic atom, whose electrons 
are more tightly held.
8
 
Electron-withdrawing substituents on the nucleophiles reduce electron density from a conjugated 
pi (π) system through the inductive effects, thereby making them less nucleophilic. This has a 
negative effect on the rate of nucleophilic substitution reactions. On the other hand, electron 
donating substituents are deemed to be activating groups as they donate electrons, thereby 
increasing the electron density in the conjugated π system by making the nucleophile more 
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nucleophilic. Consequently, this has a positive effect on the rate of reaction, possibly resulting in 
higher yields.
8
 The aforementioned, however, was generally not reflected in the results obtained 
for the isolated yields, as some of the nucleophiles with electron withdrawing groups had better 
yields than those with electron donating groups. For instance, the 4-chloroaniline and 4-
bromoaniline reactions gave better yields of 69.9% and 65.1% respectively, compared to their 
para substituted analogue of 4-methylaniline with a 54.8% isolated yield. The theory, however, 
holds true for the 4-(trifluoromethyl)-aniline reaction, which had the most electronegative 
substituent and this, was reflected by the low percentage isolated yield (35%).  
Critical parameters affecting the reaction progress such as time and temperature were 
investigated in an attempt to improve the yields. Increasing the reaction time did not result in 
complete substrate conversion in most cases, as the un-reacted naphthoquinone was still 
recovered during reaction work-up. A detailed optimisation study of the reaction conditions and 
parameters may have been the best option to improve the percentage isolated yields. At this 
stage, optimisation and improvement of the yields were not the primary objectives of the project.  
 
O
H
Et3N
O
phenoxide ion
(conjugate base)
acid
O
Scheme 3.3: The deprotonation of phenol using a triethylamine base to form the phenoxide ion. 
 
Given that phenol is a weak acidic nucleophile
9,10
, a base catalyst had to be added to the reaction 
mixture in order to deprotonate the phenol and activate it (Scheme 3.3). The phenoxide ion has a 
more stabilised resonance compared to phenol because the negative charge can be delocalised 
into the aromatic ring.
11
 Without the addition of a base, phenol was not reactive and hence could 
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not couple with 2,3-dichloro-1,4-naphthoquinone. Activation of anilines and thiols was not 
necessary, as these reactants were readily reactive (Table 3.2).  
 
Table 3.2:  Physicochemical properties of thiophenol, aniline and phenol.
10
 
Nucleophile  Physicochemical properties
10
 Relative reactivity 
 
          
SH
 
 
 
 Thiophenol 
 Acidic nucleophile 
 pKa = 9-10 
 
 
 More reactive 
  
          
NH2
 
  
 
 Aniline 
 Basic nucleophile 
 pKa = 4-5 
 
 
 Reactive 
 
          
OH
 
 
 
 Phenol 
 Acidic nucleophile 
 pKa = 9-11 
 
 
 Less reactive  
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3.2 STERIC HINDERANCE 
Nucleophilic aromatic substitution reactions involving 2-(trifluoro-methyl)-aniline and 2-
isopropyl-5-methylphenol (thymol) failed to produce any product (Table 3.1 and Scheme 3.4). 
Alterations to the reaction conditions did not yield the desired products, possibly due to steric 
hindrance by the bulky ortho substituents. Steric hindrance occurs when two atoms or functional 
groups are so close to each other that there is repulsive interaction between, them due to spatial 
crowding. This spatial arrangement of atoms or functional groups near the reacting site hinders 
the reaction from proceeding.
8
 The 
1
H NMR spectra obtained after each attempt only showed 
two multiplets of the un-reacted substrate (2,3-dichloro-1,4-naphthoquinone) that was recovered 
at the end of the reactions.  
 
O
O
Cl
Cl
NH2 OH
H3C
CH3
CH3
F
F
F
or
 
Scheme 3.4: Reaction scheme of the attempted synthesis of naphthoquinone derivatives with 2-
(trifluoromethyl)-aniline and thymol (2-isopropyl-5-methylphenol) highlighting the bulky ortho-
substituents on these nucleophiles. 
 
Steric parameters, such as the Van der Waal’s radii (Å), have been used to demonstrate that the 
trifluoromethyl group (2.20 Å) is much larger in steric bulk than the methyl group (1.80 Å).
12,13
 
This could explain why reactions with nucleophiles consisting of smaller ortho substituents 
yielded some product for example, the substitution reaction with 2-methylaniline. It could be that 
steric effects from the smaller ortho substituents possibly had a retarding effect on the relative 
reaction rate, as poor yields were obtained, whilst those from the bulky ortho substituents 
Isopropyl    
group 
Trifluoromethyl 
group 
No isolated products 
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hindered the reaction progress altogether.
8
 The trifluoromethyl group is sterically as large as the 
isopropyl group; both functional groups have a similar Van der Waal’s radius of 2.20 Å.12 
 
3.3 RECRYSTALLISATION  
Purification of the synthesised products was achieved by the process of recrystallisation from 
organic solvents. Suitable solvents were either obtained from literature or developed by a trial 
and error procedure.    
The major impurity recovered from the recrystallisation procedures was the un-reacted substrate 
of 2,3-dichloro-1,4-naphthoquinone. Thin layer chromatography (TLC) and 
1
H NMR analysis of 
almost all the recrystallised products showed traces of the naphthoquinone after the first 
recrystallisation procedure. Further purification was much needed; so the recrystallisation 
procedures were repeated in fresh solvent mixtures, or a single solvent, until traces of the 
naphthoquinone and other impurities could not be seen on the 
1
H NMR spectrum.  Melting point 
determinations also assisted in confirming whether a product had reached purity, as it would 
remain unchanged.    
It is common knowledge that after a recrystallisation procedure a product may still remain 
impure and further recrystallisation from a fresh solvent will be required. The principal 
underlying the removal of impurities by recrystallisation is the difference in solubilities between 
the product and the impurities in any given solvent. In cases where the impurity is more soluble 
than the expected product, it would be apparent that several recrystallisation procedures will 
yield a pure sample of the product.
6
   
Tandon and colleagues (2009)
5
 reported a dual method of purification of naphthoquinone 
derivatives. Firstly, the products were subjected to column chromatography and then further 
purified by recrystallisation.
5
 Use of column chromatography proved challenging as both the un-
reacted naphthoquinone and the desired product eluted at the same rate with very close Rf values. 
This can be attributed to the similarity in their functionalities as well as the polarity of their 
structures, because the naphthoquinone backbone is retained in the products. A series of 
recrystallisation procedures therefore seemed to be the best way to get rid of the un-reacted 
naphthoquinone. The stacked 
1
H NMR spectra (Figure 3.1 below) illustrates that the 
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naphthoquinone substrate was the trace impurity as its NMR signals at δ 8.22 and δ 7.79 were 
overlapping with equivalent protons in the product. Furthermore, melting point determinations of 
the isolated impurities were typically those of 2,3-dichloro-1,4-naphthoquinone which melts at 
195 ºC. This trend was observed in all the synthesised products and recrystallisation was carried 
out until a ‘clean’ 1H NMR spectrum was obtained.  
           
 
Figure 3.1: Stacked and expanded 
1
H NMR spectra of: a) isolated 2-chloro-3-phenoxy-1,4-
naphthoquinone 2a after the second recrystallisation procedure; b) a mixture of compound 2a 
and the un-reacted 2,3-dichloro-1,4-naphthoquinone after the first recrystallisation procedure; c) 
pure substrate: 2,3-dichloro-1,4-naphthoquinone; NQ = naphthoquinone. The signals highlighted 
in orange in b) are intensified compared to the same signals in a) and this is indicative of the 
trace impurity, which is the un-reacted substrate. 
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3.4 MONOSUBSTITUTED 1,4-NAPHTHOQUINONE DERIVATIVES 
The aims of the synthetic procedures were to obtain both mono- and disubstituted products by 
nucleophilic displacement of the chlorine atom(s) on the quinone with nitrogen, oxygen and 
sulphur heteroatoms of the reactants. The task proved to be a challenging one, as only 
monosubstituted products were obtained from substitution with aniline and phenol nucleophiles; 
whilst only disubstituted products were obtained from substitution with thiol nucleophiles.  
Coupling reactions of 2,3-dichloro-1,4-naphthoquione with anilines and phenols selectively 
yielded monosubstituted products (compounds 1a-1h and 2a-2e), despite the addition of two 
molar equivalents of the above mentioned nucleophiles. Figure 3.2 illustrates an expansion of 
the super-imposed 
1
H NMR spectra of the products obtained from coupling 2,3-dichloro-1,4-
naphthoquinone and aniline (1:2 ratios respectively; red spectrum) and the same reactants in a 
1:1 ratio; the blue spectrum. A similar spectrum, indicative of 2-chloro-3-(phenylamino)-1,4-
naphthoquinone (compound 1a) was obtained, despite coupling with two molar equivalents of 
the aniline. Integration of the signals gave intensity ratios corresponding to a total of ten protons 
in both spectra. The full 
1
H NMR spectra can be found in the supplementary data.  
       
Figure 3.2: Expansion of the super-imposed 
1
H NMR (600MHz, CDCl3) spectra of the product 
obtained from coupling 2,3-dichloro-1,4-naphthoquinone and aniline (1:2 ratios respectively; red 
spectrum) and the same reactants in a 1:1 ratio; blue spectrum.  
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Intensity ratios obtained from the integration of the respective 
1
H NMR spectra was the first 
evidence obtained to substantiate the formation of only monosubstituted products with respect to 
the number of protons. Furthermore, 
13
C NMR spectra of these products obtained from anilines 
and phenols all showed two quaternary carbon peaks in the region between δ 178 and δ 180 
which, is indicative of the non-equivalent carbonyl carbons present on the naphthoquinone 
backbone. 2,3-Dichloro-1,4-naphthoquinone is a symmetrical substrate and the structural 
asymmetry of the monosubstituted products can assist in explaining the occurrence of two 
carbonyl peaks.
14,15
 The 
13
C NMR spectrum of 2-chloro-3-(phenylamino)-1,4-naphthoquinone, 
compound 1a, shows the two quaternary carbon signals corresponding to the non-equivalent 
carbonyl groups (Figure 3.3). The two quaternary carbons peaks are seen in all the 
13
C NMR 
spectra of compounds 1a-1h and 2a-2e.   
 
 
Figure 3.3: 
13
C NMR (150MHz, CDCl3) spectrum of 2-chloro-3-(phenylamino)-1,4-naphtho-
quinone 1a showing the two quaternary carbon signals corresponding to the non-equivalent 
carbonyl groups. Expansion of the signals between 124 ppm and 142 ppm are shown in the off-
set plot. 
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The HPLC-ESI-MS provided molecular weights which further substantiated the formation of 
monosubstituted products from phenols and anilines.  
Electron density of the quinone backbone becomes uneven when the anilines and phenols only 
displace the chlorine atom on position three, leaving out the other on position two. Similar 
findings have been reported in literature, confirming the ease of formation of monosubstituted 
products in nucleophilic aromatic substitution reactions of naphthoquinones with anilines and 
phenols.
14,16
 Nucleophilicity of substrates has been described as one of the determining factors of 
substitution of one or both chlorine atoms of 2,3-dichloro-1,4-naphthoquinone.
3
 It has been 
reported that aryl amines of enhanced nucleophilicity substitute only one chlorine atom of 2,3-
dichloro-1,4-naphthoquinone as a result of electronic enrichment of the quinone system. An 
electron withdrawing effect ought to be imposed on the quinone ring in order to substitute the 
second chlorine atom or a catalyst be employed.
3,14
  
 
3.5 DISUBSTITUTED 1,4-NAPHTHOQUINONE DERIVATIVES 
Contrary to anilines and phenols, thiophenols selectively produced disubstituted products when 
coupled with 2,3-dichloro-1,4-naphthoquinone. It has been noted in literature that aryl thiols 
spontaneously react with 2,3-dichloro-1,4-naphthoquinone, also known as dichlone, to obtain 
2,3-bis(thio)-1,4-naphthoquinones (dithiothers)
3,17
 compared to aryl amines that yield mono-
arylamino-1,4-naphthoquinone as major products.
3
  
Use of one molar equivalent of thiol nucleophiles produced disubstituted products and attempts 
to obtain monosubstituted products using a procedure stipulated by Tandon and colleagues 
(2009)
5
 were not fruitful. Each attempt using one molar equivalent yielded a mixture of the 
disubstituted product and un-reacted 2,3-dichloro-1,4-naphthoquinone, after which the product 
was isolated by recrystallisation. Thiophenol and its aryl thiol analogues were so reactive that 
they displaced the two chlorine atoms on position two and three of the quinone backbone despite 
being the limiting reagent.  
The 
1
H NMR spectra of the products obtained from coupling with thiophenols (compounds 3a-
3e) all typically showed two multiplets, corresponding to the four protons on the quinone 
backbone. This meant protons H5 and H8 are in the same electronic environment hence they 
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resonate at the same frequency and can observed as one multiplet at δ 7.98. The same applies to 
protons H6 and H7 which were observed as a multiplet at δ 7.67 (Figure 3.4 below).  
 
 
 
Figure 3.4: 
1
H NMR (600MHz, CDCl3) spectrum of 2,3-bis(phenylthio)-1,4-naphthoquinone 3a. 
The product was obtained by coupling 2,3-dichloro-1,4-naphthoquinone with either two molar 
equivalents or one molar equivalent of thiophenol. Expansion of the signals in the aromatic 
region is shown in the off-set plot. 
 
In the 
13
C NMR spectra of the disubstituted products, compounds 3a-3e, carbon atom signals of 
the carbonyl groups were observed as one peak around δ 178. Due to the symmetrical structures, 
the two carbonyl groups are present in the same electronic environment and are equivalent; 
therefore they resonate at the same frequency and are observed as one carbonyl peak. This data 
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supports the disubstituted structural assignment of compounds 3a-3e. Recently, Ibis and 
colleagues (2013)
15
 reported the coupling of 2,3-dichloro-1,4-naphthoquinone with several other 
sulphur nucleophiles and a similar pattern was observed. These researchers also observed the two 
carbonyl groups on the naphthoquinone as one peak/signal in symmetrical structures but as two 
peaks in asymmetrical naphthoquinone derivatives.
15
  Wellington and colleagues (2012)
17
 
synthesised compound 3a via a one-pot laccase enzyme catalysed reaction and the 
13
C NMR 
spectrum of this disubstituted product also revealed one peak at δ 178.7 corresponding to the two 
equivalent carbon atoms of the quinone carbonyl groups.
17
 All the aforementioned literature 
reports further support our structural assignments of the naphthoquinone derivatives.  
 
 
Figure 3.5: 
13
C NMR (150MHz, CDCl3) spectrum of 2,3-bis(phenylthio)-1,4-naphthoquinone 
3a. One peak corresponding to the two equivalent carbonyl groups on the quinone was observed 
at δ 179. Refer to the appendix for the 13C NMR spectra of compounds 3b-3e.  
One carbonyl         
signal for                  
two carbonyl             
carbon atoms 
(C1 and C4) 
6
7
8
5
1 2
34
O
O
S
S
1'
6'
5'
4'
3'
2'
1'
6'
5'
4'
3'
2'
4a
8a
 
6
7
8
5
1 2
34
O
O
S
S
1'
6'
5'
4'
3'
2'
1'
6'
5'
4'
3'
2'
4a
8a
 
  3a  
 
Zoom in showing the 
9th peak which is not 
clearly visible in the 
full spectrum 
                                                           CHAPTER III: RESULTS & DISCUSSION - SYNTHESIS 
 
61 
 
The 
13
C NMR spectrum of compound 3a - illustrated in Figure 3.5 - revealed a total of nine 
peaks, corresponding to 22 carbon atoms. As a result of the symmetrical nature of the structure, 
carbon atoms in the same electronic environment resonate at the same frequency and share a 
similar chemical shift. Equivalent carbon atoms of compound 3a have been colour coded in its 
structure (Figure 3.5 above) and there are a total of nine colours, with each one denoting a 
carbon peak. 
 
3.6 SIMILAR 1,4-NAPHTHOQUINONES PREVIOUSLY SYNTHESISED 
Compound 1a was previously synthesised and tested for anti-fungal activity by several 
researchers, including Tandon et al.
1
 and Tran et al.
18
 The latter group of researchers also 
reported the synthesis of compounds 1b, 1c and 1d with the meta trifluoromethyl substituted 
analogue of compound 1e also being reported by this group.
18
 Benites et al.
2
 synthesised and 
evaluated compound 1f for anti-tumour activity. Compounds 2a, 2d and 2e were also synthesised 
by Tandon et al.
19
 and were evaluated for anti-fungal activity. Compound 2a was also reported 
by Lee et al.
16
 Compound 3a was obtained by Tandon et al.
5,20
 through a similar synthetic 
procedure and was evaluated for anti-fungal, anti-proliferative and anti-cancer activities. 
Wellington et al.
17
 also synthesised compound 3a using a one-pot laccase method, but no 
biological assays are mentioned in their publication. Singh et al.
21
 synthesised compounds 3a, 3c 
and 3d from oxidation of their respective 1,4-diols to produce quinones, and there was also no 
mention of any biological assays. Compound 1h, the meta substituted analogue of compound 1d, 
could not be found in the literature, nor could compounds 2b, 2c, 3b and 3d. Although some of 
the compounds have been previously synthesised and reported, none of these exact 
naphthoquinone derivatives been evaluated for anti-trypanosomal activity, to our best 
knowledge. Most researchers have focused on other biological activities, particularly anti-fungal 
activity.  
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3.7 SPECTROSCOPIC CHARACTERISATION OF THE 1,4-NAPHTHOQUINONES  
Four NMR experiments (
1
H, 
13
C, COSY and HSQC) were conducted on each of the synthesised 
products. These were considered the most crucial, in this particular project, amongst many other 
NMR experiments for structural confirmation. (Refer to the appendix for the NMR spectra of the 
all compounds.) Both 
1
H NMR and 
13
C NMR are deemed to be the most important NMR 
experiments for an organic chemist as they provide information on the number and environment 
of protons and the carbon framework of a molecule respectively.
8
 
Splitting or multiplicity in 
1
H NMR arises from a phenomena called spin coupling which, in 
simplest terms, occurs when the nucleus undergoing resonance detects the spin of a nearby active 
nuclei.
22
 Multiplicity of a resonance can be roughly predicted with the use of the n+1 rule, 
whereby a nucleus undergoing resonance which has two neighbouring/adjacent protons; will 
have its signal split into a triplet.
22
 In the 
1
H NMR spectrum, the intensity of a signal is deemed 
to be directly proportional to the number of protons that give rise to that signal.
22
 Integration of 
the peaks to obtain intensity ratios was carried out and, if the total of the intensity ratios was 
equivalent to the number of expected protons, it would be a positive start to the structural 
assignment process and a further two dimensional NMR experiments would be conducted.  
Compound 1g 2-chloro-3-(3-methoxyphenylamino)-1,4-naphthoquinone which, was obtained by 
coupling 2,3-dichloro-1,4-naphthoquinone with 3-methoxyaniline, shall be used to demonstrate 
the procedure taken for characterisation of the synthesised products. Its 
1
H NMR (Figure 3.6) 
revealed a singlet at δ 3.81, indicative of the methoxy (-OCH3) protons which have been shifted 
downfield as a result of the deshielding effects of the electronegative oxygen atom compared to 
other methyl (-CH3) containing products, whose signal resonated at δ 2.36. The rest of the 
1
H 
NMR signals (Figure 3.6) were in the aromatic region as expected: the doublets at δ 8.19 and 
8.11correspond to H8 and H5 protons respectively. The triplets at δ 7.76 and 7.69 are indicative 
of the other two protons of the naphthoquinone backbone which are H7 and H6 respectively; 
these assignments are consistent with literature.
3,18
 The -NH singlet at δ 7.66 overlaps with a 
triplet; but in some of the amino-naphthoquinone derivatives, these two signals occurred 
separately. The remaining signals resonating at δ 7.24 (t), 6.76 (dd), 6.69 (dd) and 6.61 (s) 
correspond to the H5’, H4’, H6’ and H2’ protons of the 3-methoxyaniline backbone. Upon 
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integration of the 
1
H NMR spectrum (Figure 3.6) relative to the signal at δ 8.19 which is 
responsible for only one proton, the intensity ratio indicated a total of twelve protons, supporting 
evidence that the product was monosubstituted. A disubstituted product would have been 
indicated by a total of twenty protons.  
 
 
                                                                                                                                          
Figure 3.6: 1H NMR (600MHz, CDCl3) spectrum of 2-chloro-3-(3-methoxy-phenylamino)-1,4-
naphthoquinone 1g. Expansions of signals in the aromatic region are shown in the off-set plot. 
 
The 
13
C NMR spectrum of compound 1g has two quaternary carbon signals resonating at δ 180 
and 177 (Figure 3.7), corresponding to the non-equivalent carbonyl carbon atoms which 
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signals were observed, whilst the other nine carbon signals with greater peak height/intensity are 
directly attached to protons and their carbon-proton correlations can be seen in the HSQC NMR 
spectrum (Figure 3.8). Once again, the methoxy carbon signal is shifted downfield and resonates 
at δ 55, unlike the methyl carbons in other naphthoquinone derivatives, which resonated at δ 21. 
The HSQC NMR experiments were carried out to determine which carbon signals belonged to 
carbon atoms directly attached to protons. In the HSQC NMR spectrum of compound 1g (Figure 
3.8) there existed a cross-peak at the coordinates δ (3.81; 55.26), due to the methoxy protons and 
carbon atom respectively. Eight other HSQC cross-peaks were observed.  
 
 
 Figure 3.7: 13C NMR (400MHz, CDCl3) spectrum of 2-chloro-3-(3-methoxyphenylamino)-1,4-
naphthoquinone 1g. Expansion of the signals between 126 ppm and 142 ppm are shown in the 
off-set plot. 
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Figure 3.8: HSQC NMR spectrum of 2-chloro-3-(3-methoxyphenylamino)-1,4-naphtho-
quinone 1g.  
 
The COSY NMR cross peaks, shown in Figure 3.9 below, illustrated which protons were 
adjacent to each other and, in some cases, this may be confirmatory spectral data to the coupling 
(J) constants, as pairs of coupled protons always have the same J constants.
22
 Therefore, COSY 
NMR spectra were used together with J constants to establish nearest-neighbour relationships in 
the structures of the synthesised products.  
In the HPLC-ESI-MS spectra of compound 1g (Figure 3.10) the molecular ion is observed as a 
multiple peak cluster with the base peak (most abundant ion) at m/z 316.73 [M+3H]
+
 
corresponding to the molecular weight of a monosubstituted product. The 
1
H NMR, 
13
C NMR, 
2D NMR as well as the HPLC-ESI-MS data combined assisted in structural assignments of the 
synthesised naphthoquinone derivatives.  
-OCH3               
δ (3.81; 55.26) 
C
H
HSQC  
                                                           CHAPTER III: RESULTS & DISCUSSION - SYNTHESIS 
 
66 
 
  
Figure 3.9: Expansion of the COSY NMR spectrum of 2-chloro-3-(3-methoxy-
phenylamino)-1,4-naphthoquinone 1g. 
 
        
Figure 3.10: HPLC-ESI-MS spectrum of 2-chloro-3-(3-methoxy-phenylamino)-1,4-naphtho-
quinone 1g. 
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3.8 CRYSTALLINE AND AMORPHOUS STATES OF COMPOUND 2B 
It was interesting that 2-Chloro-3-(2-chlorophenoxy)-1,4-naphthoquinone 2b existed in two 
different solid physical states - needle-shaped crystals and amorphous powder. It is widely 
known that compounds can exist in more than one solid form with different spatial arrangements 
in the atoms or molecules.
23
   
At the end of the reaction, an orange solid had crystallised out of the solution and was recovered 
by decanting the reaction mixture. The orange solid was removed from the reaction flask by 
solubilising in ethyl acetate and air dried in the fume hood, upon which pure needle-shaped 
crystals were obtained. The purity of these crystals was confirmed by 
1
H NMR. A dark yellow 
amorphous powder also precipitated out of solution when the decanted reaction mixture was 
cooled to room temperature. Unlike the orange crystals, the yellow amorphous powder had to 
undergo purification by recrystallisation. The crystals and amorphous powder showed similar 
1
H 
NMR and 
13
C NMR spectra and similar Rf values, but had different melting points. The orange 
crystals had a melting point of 178.3-181.3°C, whilst the melting point of the dark yellow 
powder was 172.1-175.7°C. This slight difference may be attributed to the different spatial 
arrangement of atoms or molecules. Crystalline compounds have a lattice with a definite shape 
and geometry, requiring higher energy to break the bonds as compared to amorphous 
compounds, which have an irregular atomic arrangement and therefore lower bond strength. 
Atoms or molecules in a crystal lattice are held together tightly, unlike those of an amorphous. In 
general, amorphous solids have lower melting points when compared to the crystalline form of 
the same compound.
23
   
Upon integration of the 
1
H NMR spectra of both solid physical states of compound 2b, intensity 
ratios of 1:1:1:2:1:1:1:1 were obtained, corresponding to a total of eight protons (Figure 3.11). 
Compound 2b has sixteen non-equivalent carbon atoms, and half of these are quaternary carbons 
whose 
13
C NMR signals are observed as short peaks as shown in Figure 3.12 below. The other 
eight carbon atoms are directly attached to protons and were observed as the longer 
13
C NMR 
peaks with similar height/intensities (Figure 3.12). These also produced cross-peaks in the 
HSQC NMR spectrum of compound 2b. The spectral data provided evidence confirming the 
structural assignments and proving that the orange needle-shaped crystals and dark yellow 
amorphous powder were chemically identical, despite the difference in their physical 
                                                           CHAPTER III: RESULTS & DISCUSSION - SYNTHESIS 
 
68 
 
appearance. Further analytical techniques such as differential scanning calorimetry (DSC) and 
thermo-gravimetric analysis (TGA) could be conducted to assess whether these two solid 
physical forms are polymorphs of each other.    
 
 
Figure 3.11: 
1
H NMR (600MHz, CDCl3) spectrum of 2-chloro-3-(2-chlorophenoxy)-1,4-
naphthoquinone 2b. Expansion of the signals is shown in the off-set plot.  The product was 
obtained by coupling 2,3-dichloro-1,4-naphthoquinone with 2-chlorophenol.  
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Figure 3.12: 
13
C NMR (150MHz, CDCl3) spectrum of 2-chloro-3-(2-chlorophenoxy)-1,4-
naphthoquinone 2b. Expansion of the signals between 118 ppm and 134 ppm is shown in the off-
set plot, which reveals the other four quaternary carbons and the eight signals of the carbon 
atoms directly attached to protons.  
 
 
3.9 INFRARED (IR) SPECTROSCOPY  
Infrared analysis was only carried out on the N-substituted 1,4-naphthoquinone derivatives 
(compounds 1a-1h) to investigate the presence of a secondary amine (-NH) functionality. The 
anilines used to synthesise compounds 1a-1h are primary amines (-NH2) and, once each couples 
to the naphthoquinone, the -NH functional group is expected. 
1
H NMR spectra of these 
compounds had a singlet around δ 7.60 which, in some cases, overlapped with a triplet signal. 
This singlet was not accounted for in the HSQC NMR spectra of compounds 1a-1h, meaning 
that the proton responsible for this signal was not attached to a carbon atom. This confirmed that 
it was the proton attached to a nitrogen atom. Infrared spectroscopy was then employed to 
Four of the eight                              
quaternary carbon       
signals 
                                                           CHAPTER III: RESULTS & DISCUSSION - SYNTHESIS 
 
70 
 
determine the type of amine present. Applications of IR spectroscopy include the detection of 
functional groups amongst others.
24
 For this reason, IR analysis was utilised, and it is known that 
the N-H stretch(s) occur in the region between 3500-3200 cm
-1
, with primary amines giving two 
bands whilst secondary amines give only one band.
24,25
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Figure 3.13: Structure of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 1a.  
 
Compounds 1a-1h gave one N-H stretch, with a frequency falling between 3219 and 3243 cm
-1
 
amongst these eight compounds. The IR and 
1
H NMR spectral data confirmed the presence of a 
secondary amine in compounds 1a-1h and that it formed the link between the naphthoquinone 
and aryl amine backbones. Figure 3.14 illustrates the IR spectrum of 2-chloro-3-(phenylamino)-
1,4-naphthoquinone 1a, highlighting the single N-H stretch at 3233 cm
-1
. 
 
Naphthoquinone      
backbone 
Aniline           
backbone 
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Figure 3.14: IR (KBr, cm
-1
) spectrum of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 
1a  highlighting the single N-H stretch at 3233 cm
-1
.  
 
In this study, IR spectroscopy was utilised for its application of functional group identification. 
Compounds 2a-2e consist of an ether linkage comprised of an sp
3
 hybridised oxygen atom 
attached to two carbon atoms: one carbon of the naphthoquinone and the other from the phenyl 
ring.
9
 There is loss of the phenolic proton during the coupling of the two substrate moieties to 
form the naphthoquinone derivative and hence the O-H stretch can no longer be seen on the IR 
spectrum. The same applies to compounds 3a-3e, which consist of thioether linkages, where an 
sp
3
 hybridised sulphur atom is attached to two carbon atoms
9
. There is loss of a proton from the 
aryl thiols during the coupling reaction, and hence the S-H stretch is absent from the IR 
spectrum. For these reasons, IR was only performed on compounds 1a-1h which had secondary 
amine linkages.  
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band 
N-H stretch              
(secondary amine) 
-C=O 
 
                                                           CHAPTER III: RESULTS & DISCUSSION - SYNTHESIS 
 
72 
 
Reference List 
 
 1.  Tandon, V. K.; Maurya, H. K. "On water": Unprecedented nucleophilic substitution and 
addition reactions with 1, 4-quinones in aqueous suspension. Tetrahedron Letters 
2009, 50 (43), 5896-5902. 
 2.  Benites, J.; Valderrama, J. A.; Bettega, K.; Pedrosa, R. C.; Calderon, P. B.; Verrax, J. 
Biological evaluation of donor-acceptor aminonaphthoquinones as antitumor 
agents. European Journal of Medicinal Chemistry 2010, 45 (12), 6052-6057. 
 3.  Tandon, V. K.; Maurya, H. K.; Mishra, N. N.; Shukla, P. K. Design, synthesis and 
biological evaluation of novel nitrogen and sulfur containing hetero-1,4-
naphthoquinones as potent antifungal and antibacterial agents. European Journal 
of Medicinal Chemistry 2009, 44 (8), 3130-3137. 
 4.  Tandon, V. K.; Yadav, D. B.; Singh, R. V.; Chaturvedi, A. K.; Shukla, P. K. Synthesis 
and biological evaluation of novel (L)-á-amino acid methyl ester, heteroalkyl, and 
aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial 
agents. Bioorganic & Medicinal Chemistry Letters 2005, 15 (23), 5324-5328. 
 5.  Tandon, V. K.; Maurya, H. K.; Tripathi, A.; ShivaKeshava, G. B.; Shukla, P. K.; 
Srivastava, P.; Panda, D. 2,3-disubstituted-1,4-naphthoquinones, 12H-
benzo[b]phenothiazine-6,11-diones and related compounds: Synthesis and 
biological evaluation as potential antiproliferative and antifungal agents. 
European Journal of Medicinal Chemistry 2009, 44 (3), 1086-1092. 
 6.  Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. Vogel's textbook of 
practical organic chemistry; 5th ed.; Longman: 1989. 
 7.  McMurry, J. Organic chemistry; 6th ed.; Brooks/Cole: 2004. 
 8.  Graham Solomons T.W.; Fryhle C.B. Organic chemistry: International student version; 
10th ed.; John Wiley & Sons: 2011. 
                                                           CHAPTER III: RESULTS & DISCUSSION - SYNTHESIS 
 
73 
 
 9.  Patrick, G. BIOS Instant notes in organic chemistry; 2nd ed.; Garland Science: 2012. 
 10.  Williams D; Lemke T Foye's Principles of medicinal chemistry; 5th ed.; Lippincott 
Williams & Wilkins: 2002. 
 11.  Clayden, J.; Greeves, N.; Warren, S. Organic chemistry; 2nd ed.; Oxford University 
Press: 2012. 
 12.  Smart, B. E. Fluorine substituent effects (on bioactivity). Journal of Fluorine Chemistry 
2001, 109 (1), 3-11. 
 13.  Hiyama, T. Organofluorine compounds: Chemistry and applications; Springer: 2000. 
 14.  Sayil, C.; Kurban, S.; Ibis, C. Synthesis and characterization of nitrogen and sulfur 
containing 1, 4-naphthoquinones. Phosphorus, Sulfur, and Silicon and the Related 
Elements 2013, (just-accepted). 
 15.  Ibis, C.; Tuyun, A. F.; Bahar, H.; Ayla, S. S.; Stasevych, M. V.; Musyanovych, R. Y.; 
Komarovska-Porokhnyavets, O.; Novikov, V. Synthesis of novel 1, 4-
naphthoquinone derivatives: Antibacterial and antifungal agents. Medicinal 
Chemistry Research 2013, 1-10. 
 16.  Lee, D. M.; Ko, J. H.; Lee, K. I. Cesium carbonate-mediated reaction of 
dichloronaphthoquinone derivatives with O-nucleophiles. Monatsh. Chem. 2007, 
138 (8), 741-746. 
 17.  Wellington, K. W.; Bokako, R.; Raseroka, N.; Steenkamp, P. A one-pot synthesis of 1, 4-
naphthoquinone-2, 3-bis-sulfides catalysed by a commercial laccase. Green 
Chemistry 2012, 14 (9), 2567-2576. 
 18.  Tran, N. C.; Le, M. T.; Nguyen, D. N.; Tran, T. D.  Synthesis and biological evaluation 
of halogen substituted 1,4-naphthoquinones as potent antifungal agents.  
                        Ref Type: Online Source 
https://www.usc.es/congresos/ecsoc/13/hall_c_BMNPC/c12.pdf (accessed: 
19/05/13) 
                                                           CHAPTER III: RESULTS & DISCUSSION - SYNTHESIS 
 
74 
 
 19.  Tandon, V. K.; Maurya, H. K.; Mishra, N. N.; Shukla, P. K. Micelles catalyzed 
chemoselective synthesis "in water" and biological evaluation of oxygen 
containing hetero-1,4-naphthoquinones as potential antifungal agents. Bioorganic 
& Medicinal Chemistry Letters 2011, 21 (21), 6398-6403. 
 20.  Tandon, V. K.; Chhor, R. B.; Singh, R. V.; Rai, S.; Yadav, D. B. Design, synthesis and 
evaluation of novel 1,4-naphthoquinone derivatives as antifungal and anticancer 
agents. Bioorganic Medicinal Chemistry Letters 2004, 14 (5), 1079-1083. 
 21.  Singh, W. M.; Baruah, J. B. Synthesis of mixed aryl 2,3-diarylsulphanyl-1,4-
naphthoquinones. Synthetic Communications 2009, 39 (8), 1433-1442. 
 22.  Young, PR. Practical spectroscopy: The rapid interpretation of spectral data for 
McMurry's organic chemistry; 5th ed.; Brooks/Cole: 2000. 
 23.  Pandit, N. K. Introduction to pharmaceutical sciences; 1st ed.; Lippincott Williams & 
Wilkins: 2007. 
 24.  Yadav, L. D. S. Organic spectroscopy; Kluwer Academic Publishers: 2005. 
 25.  Smith, B. C. Infrared spectral interpretation: A systemic approach; CRC Press: 1999. 
 
 
   
75 
 
CHAPTER IV: RESULTS AND DISCUSSION OF THE BIOLOGICAL ASSAYS 
 
4.1 INTRODUCTION 
Structure-activity relationship (SAR) is a paradigm relating the structure of a molecule to its 
biological activity. The concept is used by medicinal chemists in their quest to discover better 
drugs and it entails the modification of functional groups within a series of analogous 
compounds in search of more potent, selective and safer drugs.
1,2
  
The relationship between the molecular structure of a compound and its biological activity has 
been studied since the nineteenth century. In 1869, Crum-Brown and Fraser demonstrated that 
some compounds, such as the pain-killer morphine, with tertiary amine groups acted as muscle 
relaxants when converted to quaternary ammonium compounds.
1,2
  
Although there was much debate that followed with regards to this hypothesis, Crum-Brown and 
Fraser’s discovery prompted other scientists to begin searching for organic functional groups that 
would produce specific biological activities. This became the foundation of structure-activity 
relationship studies.
1
  
The hallmarks of SAR studies are said to be the synthesis of a number of analogues and their 
testing for activity to determine the effects of small changes in chemical structure on the 
potency.
2
 In this case, an SAR study was conducted to assess the relationships between structure 
and anti-trypanosomal activity. 
Quantitative structure-activity relationships (QSARs) pertain to the chemical and physical 
properties that describe the association between structure and property. QSARs are defined by 
biological, physical and intrinsic properties (Figure 4.1). These rely on the ability to investigate 
multiple relationships between biological and physical properties.
1
 The historic development of 
QSARs involves contributions by Richet, Ferguson, Taft, Hammett, Hansch and Fujita, amongst 
others.
3
 The Hansch-type analysis is a classic QSAR that affords an equation defining biological 
activities as a linear free energy relationship.
1
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Figure 4.1: Properties that define quantitative structure activity relationships (QSARs): 
biological, physical and intrinsic properties.
1
 MWt = molecular weight, IC50 = concentration 
required to produce 50% inhibition of cell growth and EC50 refers to 50% of the maximal 
effective concentration.  
 
SARs and QSARs of a series of analogous 1,4-naphthoquinone derivatives shall be discussed in 
this chapter. The aim of this particular QSAR study was to investigate the electron-donating or 
withdrawing effects of the substituents on anti-trypanosomal activity. This study investigated the 
correlation between only two descriptors of QSARs, namely Hammett substituent constant (σ), 
an electronic property, and EC50, a biological property. The σ constants are electronic descriptors 
which quantify the electron donating or withdrawal potency of substituents on aromatic rings and 
they were put forward by Hammett in 1940.
4,5
 Values of σ constants are dimensionless and are 
described with respect to the meta or para position of the substituent on a benzene ring. The 
effects of substituents on the reaction centre differ in the ortho, para and meta positions as a 
result of variable inductive, resonance and steric effects. The σ values are generally deemed to be 
constant for a particular substituent and are relative to hydrogen whose value is, by definition, set 
to zero.
4
 The σ values of the substituents investigated in this study are 4-Cl: 0.23, 4-Br: 0.23, 4-
CH3: -0.17, 3-CH3: -0.07, 4-CF3: 0.54 and 3-OCH3: 0.12.
6
     
Biological properties: 
 IC50 
 EC50 
 Efficacy 
Physical properties: 
 Steric (Es) 
 Electronic (σ) 
 Lipophilic (π) 
Intrinsic properties: 
 MWt 
 Volume 
 Surface area 
                            
QSARs 
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Whilst Hammett constants have been used to quantify the electronic effects of para and meta 
substituents, the same is usually not applicable to ortho substituents. The initial Hammett 
equation does not hold for ortho substituents, as they are adjacent to the reaction centre 
(nucleophilic centre in this situation) and hence, a variety of proximity effects such as steric 
effects come into play. This does not give a true reflection of electronic effects as the ortho 
substituents are governed by both electronic and steric effects.
7
 It is for this reason compounds 
with ortho substituents were left out during the QSAR analysis.  
 
4.2 SAR & QSAR STUDY OF 1,4-NAPHTHOQUINONE DERIVATIVES 
4.2.1 Phenylamino containing 1,4-naphthoquinones  
 
Table 4.1: Hammett substituent constants (σ), 50% of the maximal effective concentration 
(EC50) and the negative logarithm of one over EC50 values of naphthoquinone derivatives 
prepared from anilines.   
Compound Phenylamino 
ring substituent 
σ constant EC50 (µM) -log(1/EC50) 
1a 
 
-H  0.00 12.59 1.10 
1b 
 
4-Cl  0.23 <50.12 --- 
1c 
 
4-Br  0.23 10.96 1.04 
1d 
 
4-CH3 -0.17 2.454 0.39 
1e 
 
4-CF3  0.54 2.137 0.33 
1f 
 
2-CH3  ---- 2.818 0.45 
1g 
 
3-OCH3  0.12 2.511 0.40 
1h 3-CH3 -0.07 2.754 0.44 
 
Hammett substituent constants (σ), 50% of the maximum effective concentration (EC50) and the 
negative logarithm of one over EC50 values of 2-chloro-3-(substituted phenylamino)-1,4-
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naphthoquinones (compounds 1a-1h) are given in Table 4.1 above. The lower the EC50 value of 
any given compound, the more potent it is.
8
 The EC50 (µM) data set was plotted against the 
phenylamino substituent in order to present a graphical picture of the data (Figure 4.2).  
 
 
Figure 4.2: Graphic representation of the EC50 values of 2-chloro-3-(substituted phenylamino)-
1,4-naphthoquinones (1a,1c-1h) where R is the phenylamino ring substituent. Compound 1b has 
been excluded as a result of a lack of potency.  
 
Figure 4.2 illustrates that substititution of the phenylamino ring increases potency, as the non-
substituted ring gave the lowest potent 1,4-naphthoquinone derivative (compound 1a, EC50 = 
12.59 µM). Substitution of the phenyl amino ring with bromine on the para position (compound 
1c), increased potency slightly in comparison to the non-substituted phenyl amino ring. 
Substitution with a trifluoromethyl group on the para position gave the most potent 2-chloro-3-
(substituted phenylamino)-1,4-naphthoquinone (compound 1e), which is 6-fold more potent than 
the non-substituted phenylamino derivative (compound 1a).  
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The position of methyl substituent on the phenylamino ring has no huge effect on potency as the 
para (1d), ortho (1f) and meta (1h) methyl substituted 2-chloro-3-(substituted phenylamino)-1,4-
naphthoquinones gave almost similar EC50 values of 2.454, 2.818 and 2.754 µM respectively.  
Substitition of the phenylamino ring with a methoxy or methyl groups on the meta position 
resulted in almost  equipotent compunds 1g and 1h, with EC50 values of 2.511 and 2.754 µM 
respectively. Depending on the position, a methoxy substituent can either donate or withdraw 
electrons. In the meta position, electronegativity of the methoxy oxygen atom produces an 
inductive effect on the withdrawal of electrons.
6
 However, this had no huge effect on potency 
because presence (m-OCH3) or absence of the oxygen atom (m-CH3) on the phenylamino ring 
resulted in almost equipotent compounds 1g and 1h respectively.  
Amongst the 2-chloro-3-(substituted phenylamino)-1,4-naphthoquinones, only the para chloro 
substituted compound 1b had little or no potency, hence its absence in Figure 4.2. 
Electronegativity of the chlorine substituent (3.19) could not be employed to explain why 
compound 1b lacked potency because the trifluoromethyl substituted compound 1e showed the 
greatest potency in the series of analogous compounds, yet it is more electronegative (3.30).
9
   
 A similar trend of the effects of halogens on potency was obtained with an SAR study of 
monoamine oxidase (MAO) inhibitors.
10
 A bromine substituent increased potency whilst a 
trifluoromethyl substituent made the MAO inhibitors even more potent (Table 4.2 below).
10
 This 
trend was also observed in this study whereby a bromine substituent on the phenylamino ring 
gave a better potency than a non-substituted phenylamino ring and a trifluoromethyl group 
enhanced the potency even further. 
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Table 4.2: The influence of halogen substituents on in vitro potency.  
MAO inhibitor 
10 
2-chloro-3-(substituted phenylamino)-1,4-
naphthoquinones from the current study 
X IC50 (µM) X EC50 (µM) 
-H 
-Br 
-CF3 
1.20 
0.20 
0.10 
-H (1a) 
-Br (1c) 
-CF3 (1e) 
12.59 
10.96 
2.137 
 
 
 
 
 
 
 
 
 
A quantitative structure activity relationship (QSAR) was carried out to investigate if a 
correlation between the potency of 2-chloro-3-(substituted phenylamino)-1,4-naphthoquinones 
(1a,1c-1h) and electron-donating or withdrawing properties of substituents exists. A scatter 
graph of the negative logarithm of one over the EC50 against the σ constants showed that there is 
no linear correlationship between potency and the substituent effect (Figure 4.3).  
A correlation coefficient (r
2
) very close to one means that there is a linear correlation between 
any two variables; however, a value very close to zero indicates that there is no correlation.
11
 The 
line of best fit from the plot illustrated in Figure 4.3 gave an r
2
 value of 0.0053, hence the 
regression equation does not fit the data. This goes to show that substituent effects on the 
phenylamino ring are not directly proportional to potency. The equation of the line can be given 
as log (1/EC50) = 0.1009σ - 0.6276 and, since the regression analysis suggests that there is a non-
linear correlation, the equation therefore cannot be used to estimate the potency.   
 
O
O
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O
X
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Figure 4.3: The effects of electronic properties (σ) of the substituent on the potency of 2-chloro-
3-(substituted phenylamino)-1,4-naphthoquinones, compounds 1a,1c-1h.  
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4.2.2 Phenoxy containing 1,4-naphthoquinones 
EC50, σ constants and the negative logarithm of one over EC50 values of 2-chloro-3-(substituted 
phenoxy)-1,4-naphthoquinone, compounds 2a-2e, are given in Table 4.3. Compounds 2b and 2c 
have ortho substituents, and hence their σ constant values were not given, as ortho substituents 
have been said to have some steric effects on the reactive group or centre.
7
   
 
Table 4.3: Hammett substituent constants (σ), EC50 and the negative logarithm of one over EC50 
values of naphthoquinone derivatives prepared from phenols.   
Compound Phenoxy ring 
substituent 
σ constant EC50  (µM) -log(1/EC50) 
2a 
 
-H  0.00 5.888 0.770 
2b 
 
2-Cl --- 6.025 0.780 
2c 
 
2-Cl,4-CH3 --- 3.89 0.590 
2d 
 
3,5-CH3 ---  5.370 0.730 
2e 
 
4-Cl -0.17 6.760 0.829 
 
Amongst the 2-chloro-3-(substituted phenoxy)-1,4-naphthoquinone series, compound 2c was the 
most potent, with an EC50 of 3.89 µM. The structural difference between compounds 2b and 2c 
is the additional para substituted methyl group on the phenoxy ring of the latter compound. 
Presence of this methyl group increased potency by almost 2-fold (Figure 4.4). The 3,5-dimethyl 
substituted phenoxy ring of compound 2d was slightly more potent than the non-substituted ring 
of compound 2a.  
Chloro-substitution of the phenoxy ring on the ortho position increased potency slightly when 
compared to substituting the same functional group on the para position, as compounds 2b and 
2e had EC50 values of 6.025 and 6.760 µM respectively. Absence of a substituent in the phenoxy 
ring (compound 2a) results in better potency compared to the chloro substitution of the same ring 
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(compounds 2b and 2e). The order of potency amongst the 2-chloro-3-(substituted phenoxy)-1,4-
naphthoquinone series illustrated in Figure 4.4 is as follows: compound 2c > 2d > 2a > 2b > 2e.     
 
 
 
Figure 4.4: Graphic representation of the EC50 values of 2-chloro-3-(substituted phenoxy)-1,4-
naphthoquinones (compounds 2a-2e) where R is the phenoxy ring substituent.  
 
4.2.3 Bis-thiophenyl containing 1,4-naphthoquinones 
 EC50, σ constants and the negative logarithm of one over EC50 values of 2,3-bis(substituted 
thiophenyl)-1,4-naphthoquinones (disubstituted compounds 3a, 3b and 3d) are given in Table 
4.4. Compound 3e has an ortho substituent and hence its σ constant value is not given due to the 
steric effects on the reactive group/centre.
7
 The EC50 (µM) data set was plotted against the 
thiophenyl substituent in order to produce a graphical picture of the data (Figure 4.5). 
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Table 4.4: Hammett substituent constants (σ), EC50 and the negative logarithm of one over EC50 
values of naphthoquinone derivatives prepared from thiophenols. 
Compound Thiophenyl ring 
substituent 
σ constant EC50 (µM) -log(1/EC50) 
3a 
 
-H  0.00 2.884 0.46 
3b 
 
4-Cl  0.23 32.36 1.51 
3c 
 
4-Br  0.23 <50.12 --- 
3d 
 
4-CH3 -0.17 7.244 0.86 
3e 
 
2-CH3  ---- <50.12 --- 
 
 
 
Figure 4.5: Graphical representation of the EC50 values of 2,3-bis(substituted thiophenyl)-1,4-
naphthoquinones (compounds 3a, 3b and 3d) where R is the thiophenyl ring substituent. 
Compounds 3c and 3e have been excluded as a result of their lack of potency.  
 
Compound 3a had the highest potency amongst the 2,3-bis(substituted thiophenyl)-1,4-naphtho-
quinones and it has a non-substituted thiophenyl ring. Substitution on the para position with 
methyl or chloro groups reduced the potency (Figure 4.5). Introduction of a halogen substituent 
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on the thiophenyl drastically reduced the potency as compound 3b was 11-fold less potent than 
compound 3a. Presence of the methyl substituent (compound 3d) reduced the potency by almost 
3-fold in comparison to compound 3a, which has no thiophenyl substituent. However, 
substitution with the electron-donating methyl group resulted in better potency compared to 
substitution with the electron-withdrawing chlorine atom. Substitution of the thiophenyl ring 
with a bromine atom (compound 3c) resulted in a lack of potency and the same was observed 
with substitution with a methyl group on the ortho position (compound 3e), explaining their 
absence in Figure 4.5 above.    
A QSAR study was conducted to investigate if a correlation between the potency of 2,3-
bis(substituted thiophenyl)-1,4-naphthoquinones (compounds 3a, 3b and 3d) and the electron-
donating or withdrawing properties of the substituents exists. A scatter plot of the negative 
logarithm of one over the EC50 against the σ constant revealed that the relationship between these 
two variables is non-linear as an r
2 
value of 0.4612 was obtained (Figure 4.6). Therefore, 
potency was not directly proportional to the substituent effects. The equation of the line can be 
given as: log (1/EC50) = 1.7928σ - 0.9075, and since the regression analysis suggests that there is 
a non-linear correlation, the equation therefore cannot be used to predict the potency.   
 
        
Figure 4.6: The effects of electronic properties (σ) of the substituent on the potency of 2,3-
bis(substituted thiophenyl)-1,4-naphthoquinones (compounds 3a,3b and 3d).   
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4.2.4 General discussion   
In this study, the reference standard used was melarsoprol, a melaminophenyl-based organic 
arsenical compound (Figure 4.7) currently used in the treatment of stage 2 of either the T.b. 
gambiense form or the T. b. rhodesiense form of sleeping sickness.
12
 Melarsoprol was very 
potent compared to the synthesised 1,4-naphthoquinone derivatives. It was 142-fold more potent 
than 2-chloro-3-(4-(trifluoromethyl)phenylamino)-1,4-naphthoquinone 1e, which was the most 
potent compound amongst the series of 1,4-naphthoquinone derivatives (Figure 4.8).  
Although melarsoprol showed a high degree of potency, the drug is very toxic and results in 
treatment-related deaths in approximately 5% of patients treated with it.
13
 The toxicity may 
possibly be conferred by the arsenic containing moiety.  
                                   
                                       OH
S
As
S
H
NN
NN
H
2
N
H2N
 
Figure 4.7: The structure of melarsoprol, a drug currently used for the treatment of sleeping 
sickness.  
 
The substrate of 2,3-dichloro-1,4-naphthoquinone was also tested for potency in order to 
investigate the effects of coupling with aniline, phenol and thiophenol nucleophiles. Figure 4.8 
illustrates that 2,3-dichloro-1,4-naphthoquinone, denoted as NQ, is equipotent to compounds 2e 
and 3d. Furthermore, it is more potent than compounds 1a, 1c and 4-fold more than compound 
3b. This means that displacement of the chlorine atom on position three of 2,3-dichloro-1,4-
naphthoquinone with a phenylamino ring (1a) or a 4-bromophenylamino ring (1c) results in the 
reduction of anti-trypanosomal activity. Compounds 1d-1h and 3a are twice as potent as the 
starting material (2,3-dichloro-1,4-naphthoquinone), as can be seen in Figure 4.8.  
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Replacement of an amino linkage (-NH-) with an ether linkage (-O-) increased the potency by 2-
fold, as demonstrated by the EC50 values of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 1a 
and 2-chloro-3-(phenoxy)-1,4-naphthoquinone 2a of 12.39 and 5.888 µM respectively. Presence 
of a thioether linkage (-S-) and disubstitution of both chlorine atoms of 2,3-dichloro-1,4-
naphthoquinone results in an increment of potency, as compound 3a had an EC50 value of 2.888 
µM compared to the starting material, 2,3-dichloro-1,4-naphthoquinone, with an EC50 value of 
7.244 µM. Compounds with the best in vitro anti-trypanosomal potencies in the series of 
analogous 1,4-naphthoquinone derivatives had EC50 values in the range 2.137 to 2.884 µM 
(Figure 4.8). 
      
Figure 4.8: Comparison of the potency of 1,4-naphthoquinone derivatives as well as 2,3-
dichloro-1,4-naphthoquinone (NQ) and melarsoprol (reference standard) against T.brucei.  
Compounds 1b, 3c and 3e have been excluded as a result of a lack of potency. 
 
Compounds 1b, 3c and 3e had poor or lack of anti-trypanosomal activity and their EC50 values 
were reported as less than 50.12 µM and were therefore excluded from the graphs.  Dose-
response curves of these 1,4-naphthoquinone derivatives (Figure 4.9) are a graphical 
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representation illustrating their poor or lack of anti-trypanosomal activity. A standard dose-
response curve is defined by four parameters which make up the four parametric equation given 
in section 2.3.3 of Chapter 2. The parameters are baseline response (bottom), maximum response 
(top), EC50 and Hill slope
14,15
; these could not be obtained for compounds 1b, 3c and 3e. The rest 
of the compounds of the series of 1,4-naphthoquinone derivatives produced sigmoid-shaped 
dose-response curves, each with a single plateau (monophasic). For example, 2-chloro-3-(4-
(trifluoromethyl)phenylamino)-1,4-naphtho-quinone 1e, the most potent compound of the series, 
produced a sigmoidal dose-response curve with a Hill slope of 2.59 (Figure 4.9). The Hill slope 
refers to the steepness of a curve and a dose-response curve with a standard slope is said to have 
a Hill slope of 1.
15
      
 
       
 
 
       
Figure 4.9: Dose-response curves of the 1,4-naphthoquinone derivatives that showed poor or 
lack of anti-trypanosomal activity (compounds 1b, 3c and 3e) in compassion to the 1,4-naphtho-
quinone derivative that showed the highest potency (compound 1e).  
 3c 
  3e 
 1e 
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CHAPTER V: CONCLUSION 
 
Eighteen 1,4-naphthoquinone derivatives were successfully synthesised using ethanolic 
solutions. Structural confirmation and purity of these compounds were confirmed using 
spectroscopic methods and melting point determination. Unfortunately, attempts to synthesise 
1,4-naphthoquinones in reactions involving 2-(trifluoro-methyl)aniline and 2-isopropyl-5-
methylphenol (thymol) were unsuccessful, presumably due to steric hindrance by the bulky 
ortho-substituents.   
Although the aims of the synthetic procedures were to obtain both mono- and disubstituted 
products by nucleophilic displacement of the chlorine atom(s), only monosubstituted products 
were obtained from substitution with aniline and phenol nucleophiles. Thiol nucleophiles 
selectively yielded only disubstituted products.   
Synthesised naphthoquinone derivatives were successfully tested against T.brucei and the 
calculation of EC50 values from the obtained dose-response curves was carried out using a four 
parametric equation. All the 1,4-naphthoquinones showed a degree of potency except 
compounds 1b, 3c and 3e which had little or no potency. 
An SAR study was successfully conducted to determine which structural features or substituents 
of the naphthoquinone derivatives contribute or detract from the desired anti-trypanosomal 
activity.  
Three types of nucleophiles were used namely phenols, thiophenols as well as anilines, and the 
synthesised 1,4-naphthoquinone derivatives contained ether, thioether and amino linkages 
respectively. Presence of an ether linkage (-O-) increased the potency by 2-fold in comparison to 
the amino linkage (-NH-) as demonstrated by compounds 2a and 1a respectively. A thioether 
linkage (-S-) and disubstitution of both chlorine atoms of 2,3-dichloro-1,4-naphthoquinone 
(compound 3a) resulted in further increment in potency compared to compounds 1a and 2a. 
Electron-withdrawing chloro substituents on the phenoxy ring of 2-chloro-3-(substituted 
phenoxy)-1,4-naphthoquinone reduce potency whilst the presence of electron donating methyl 
substituents on the same ring increases potency. Position of methyl substituent on the 
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phenylamino ring had no huge effect on potency as the para (1d), ortho (1f) and meta (1h) 
methyl substituted 2-chloro-3-(substituted phenylamino)-1,4-naphthoquinones yielded almost 
similar EC50 values. In addition, meta substitition of the phenylamino ring with a methoxy or 
methyl groups also had no huge effect on the potency. 
The starting material (2,3-dichloro-1,4-naphthoquinone) was found to be potent against T.brucei 
and this can be attributed to its 1,4-ketone motif. This substrate was equipotent to compound 3d 
but more potent than compounds 1a, 1c, and 3b.   
Compounds with the best in vitro anti-trypanosomal potencies in the series of analogous 1,4-
naphthoquinone derivatives had EC50 values in the range 2.137 to 2.884 µM. The most potent 
compound in the series was 2-chloro-3-(4-(trifluoromethyl)phenylamino)-1,4-naphthoquinone 
1e; but this was 142-fold less potent than reference standard of melarsoprol.  
QSARs were also conducted to investigate the electron donating or withdrawing effects of the 
substituents on anti-trypanosomal activity, but these excluded ortho-substituent containing 1,4-
naphthoquinones derivatives.  
The relationship between electronic properties (σ) of the substituent effect and the potency of 
2,3-bis(substituted thiophenyl)-1,4-naphthoquinones (compounds 3a,3b and 3d) and 2-chloro-3-
(substituted phenyl-amino)-1,4-naphtho-quinones (compounds 1a,1c-1h) were non-linear. This 
was demonstrated by r
2
 values that were close to zero and their regression equations therefore 
cannot be used to predict the potency.   
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APPENDIX 
 
 
 SPECTROSCOPIC DATA 
BIOLOGICAL ACTIVITY DATA 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                   Spectroscopic data: Compound 1a 
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COMPOUND 1a 
 
 
1
H NMR (600MHz, CDCl3) spectrum of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 1a. The 
product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with aniline. Expansion of 
the aromatic region is shown in the off-set plot. 
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                                                                                                   Spectroscopic data: Compound 1a 
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13
C NMR (150MHz, CDCl3) spectrum of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 1a. 
Expansion of the signals between 124 ppm and 142 ppm are shown in the off-set plot. 
 
aromatic 
carbons  
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                                                                                                   Spectroscopic data: Compound 1a 
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                  Full COSY NMR spectrum of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 1a. 
 
 
                                                                                                   Spectroscopic data: Compound 1a 
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Expansion of the COSY NMR spectrum of 2-chloro-3-(phenylamino)-1,4-naphtho-
quinone 1a  showing the aromatic region only. 
 
 
 
 
 
  
                                                                                                   Spectroscopic data: Compound 1a 
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        Full HSQC NMR spectrum of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 1a. 
 
 
                                                                                                   Spectroscopic data: Compound 1a 
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Expansion of the HSQC NMR spectrum of 2-chloro-3-(phenylamino)-1,4-
naphthoquinone 1a  showing the aromatic region only. 
 
 
                                                                                                   Spectroscopic data: Compound 1a 
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HPLC-ESI-MS spectrum of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 1a. 
 
 
 
 
 
 
                                                                                                   Spectroscopic data: Compound 1a 
 
101 
 
 
                 IR (KBr, cm
-1
) spectrum of 2-chloro-3-(phenylamino)-1,4-naphthoquinone 1a. 
 
-NH stretch              
(secondary amine)  
shoulder            
band 
-C=O 
                                                                                                    Spectroscopic data: Compound 1b 
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COMPOUND 1b 
 
 
1
H NMR (600MHz, CDCl3) spectrum of 2-chloro-3-(4-chloro-phenylamino)-1,4-naphthoquinone 
1b. The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with aniline. 
Expansions of signals in the aromatic region are shown in the off-set plot. 
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                                                                                                    Spectroscopic data: Compound 1b 
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13
C NMR (100MHz, DMSO-d) spectrum of 2-chloro-3-(4-chloro-phenylamino)-1,4-
naphthoquinone 1b. Expansion of the signals between 110 ppm and 145 ppm are shown in the 
off-set plot. 
 
 
                                                                                                    Spectroscopic data: Compound 1b 
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          Full COSY NMR spectrum of 2-chloro-3-(4-chloro-phenylamino)-1,4-naphthoquinone 1b. 
                                                                                                    Spectroscopic data: Compound 1b 
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Expansion of the COSY NMR spectrum of 2-chloro-3-(4-chloro-phenylamino)-1,4-naphtho-
quinone 1b. 
 
                                                                                                    Spectroscopic data: Compound 1b 
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Expansion of the HSQC NMR spectrum of 2-chloro-3-(4-chloro-phenylamino)-1,4-naphtho-
quinone 1b. 
 
                                                                                                    Spectroscopic data: Compound 1b 
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HPLC-ESI-MS spectrum of 2-chloro-3-(4-chloro-phenylamino)-1,4-naphthoquinone 1b. 
 
                                                                                                    Spectroscopic data: Compound 1b 
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           IR (KBr, cm
-1
) spectrum of 2-chloro-3-(4-chloro-phenylamino)-1,4-naphthoquinone 1b. 
 
                                                                                                    Spectroscopic data: Compound 1c 
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COMPOUND 1c 
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1
H NMR (600MHz, CDCl3) spectrum of 2-chloro-3-(4-bromophenylamino)-1,4-
naphthoquinone 1c. The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone 
and 4-bromoaniline. Expansions of the signals in the aromatic region are shown in the off-set 
plot. 
 
                                                                                                    Spectroscopic data: Compound 1c 
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2x -C=O 
13
C NMR (150MHz, CDCl3) spectrum of 2-chloro-3-(4-bromo-phenylamino)-1,4-
naphthoquinone 1c. Expansion of the signals between 126 ppm and 142 ppm are shown 
in the off-set plot. 
 
                                                                                                    Spectroscopic data: Compound 1c 
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       Full COSY NMR spectrum of 2-chloro-3-(4-bromo-phenylamino)-1,4-naphthoquinone 1c.  
 
                                                                                                    Spectroscopic data: Compound 1c 
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Expansion of the COSY NMR spectrum of 2-chloro-3-(4-bromo-phenylamino)-1,4-
naphthoquinone 1c.  
 
                                                                                                    Spectroscopic data: Compound 1c 
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         Full HSQC NMR spectrum of 2-chloro-3-(4-bromo-phenylamino)-1,4-naphthoquinone 1c.  
 
                                                                                                    Spectroscopic data: Compound 1c 
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Expansion of HSQC NMR spectrum of 2-chloro-3-(4-bromo-phenylamino)-1,4-
naphthoquinone 1c.  
 
                                                                                                    Spectroscopic data: Compound 1c 
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HPLC-ESI-MS spectrum of 2-chloro-3-(4-bromo-phenylamino)-1,4-naphthoquinone 1c.  
 
 
 
 
 
 
                                                                                                    Spectroscopic data: Compound 1c 
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       IR (KBr, cm
-1
) spectrum of 2-chloro-3-(4-bromo-phenylamino)-1,4-naphthoquinone 1c.  
 
 
 
                                                                                                    Spectroscopic data: Compound 1d 
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COMPOUND 1d 
 
 
 
 
1
H NMR (400MHz, CDCl3) spectrum of 2-chloro-3-(p-tolylamino)-1,4-naphthoquinone 1d. The 
product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 4-methylaniline. 
Expansions of signals in the aromatic region as well as the methyl signal are shown in the off-set 
plot. 
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                                                                                                    Spectroscopic data: Compound 1d 
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13
C NMR (100MHz, CDCl3) spectrum of 2-chloro-3-(p-tolylamino)-1,4-naphthoquinone 1d. 
Expansion of the signals between 124 ppm and 136 ppm are shown in the off-set plot. 
 
-C=O -CH3 
                                                                                                    Spectroscopic data: Compound 1d 
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                     Full COSY NMR spectrum of 2-chloro-3-(p-tolylamino)-1,4-naphthoquinone 1d. 
 
 
                                                                                                    Spectroscopic data: Compound 1d 
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Expansion of the COSY NMR spectrum of 2-chloro-3-(p-tolylamino)-
1,4-naphthoquinone 1d. 
 
                                                                                                    Spectroscopic data: Compound 1d 
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     Full HSQC NMR spectrum of 2-chloro-3-(p-tolylamino)-1,4-naphthoquinone 1d. 
-CH3 
                                                                                                    Spectroscopic data: Compound 1d 
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Expansion of the HSQC NMR spectrum of 2-chloro-3-(p-tolylamino)-1,4-
naphthoquinone 1d. The methyl correlation cannot be seen here.  
 
                                                                                                    Spectroscopic data: Compound 1d 
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HPLC-ESI-MS spectrum of 2-chloro-3-(p-tolylamino)-1,4-naphthoquinone 1d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                    Spectroscopic data: Compound 1d 
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         IR (KBr, cm
-1
) spectrum of 2-chloro-3-(p-tolylamino)-1,4-naphthoquinone 1d. 
 
                                                                                                    Spectroscopic data: Compound 1e 
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COMPOUND 1e 
 
 
1
HNMR (400MHz,CDCl3) spectrum of 2-chloro-3-(4-(trifluoro-methyl)phenylamino)-1,4-
naphthoquinone 1e. The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone 
with 4-(trifluoromethyl)aniline. 
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                                                                                                    Spectroscopic data: Compound 1e 
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13
C NMR (100MHz, CDCl3) spectrum of 2-chloro-3-(4-(trifluoro-methyl)phenylamino)-1,4-
naphthoquinone 1e. Expansion of the signals between 118 ppm and 142 ppm are shown in the 
off-set plot. 
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                                                                                                    Spectroscopic data: Compound 1e 
 
127 
 
 
Full COSY NMR spectrum of 2-chloro-3-(4-(trifluoro-methyl)phenylamino)-1,4-
naphthoquinone 1e. 
 
                                                                                                    Spectroscopic data: Compound 1e 
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 Expansion of the COSY NMR spectrum of 2-chloro-3-(4-(trifluoromethyl)-phenylamino)-
1,4-naphthoquinone 1e. 
 
                                                                                                    Spectroscopic data: Compound 1e 
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 Full HSQC NMR spectrum of 2-chloro-3-(4-(trifluoromethyl)-phenylamino)-1,4-
naphthoquinone 1e. 
 
                                                                                                    Spectroscopic data: Compound 1e 
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Full HSQC NMR spectrum of 2-chloro-3-(4-(trifluoro-methyl)phenylamino)-1,4-
naphthoquinone 1e. 
 
 
 
 
 
 
 
 
 
 
                                                                                                    Spectroscopic data: Compound 1e 
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HPLC-ESI-MS spectrum of 2-chloro-3-(4-(trifluoromethyl)phenylamino)-1,4-naphthoquinone 1e. 
 
                                                                                                    Spectroscopic data: Compound 1e 
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IR (KBr, cm
-1
) spectrum of 2-chloro-3-(4-(trifluoromethyl)phenylamino)-1,4-naphtho-
quinone 1e. 
 
                                                                                                    Spectroscopic data: Compound 1f 
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COMPOUND 1f 
 
 
1
H NMR (600MHz, CDCl3) spectrum of 2-chloro-3-(o-tolylamino)-1,4-naphthoquinone 1f. The 
product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 2-methylaniline. 
Expansions of signals in the aromatic region as well as the methyl signal are shown in the off-set 
plot. 
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                                                                                                    Spectroscopic data: Compound 1f 
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13
C NMR (150MHz, CDCl3) spectrum of 2-chloro-3-(o-tolylamino)-1,4-naphthoquinone 1f. 
Expansion of the signals between 126 ppm and 137 ppm are shown in the off-set plot. 
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                                                                                                    Spectroscopic data: Compound 1f 
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        Full COSY NMR spectrum of  2-chloro-3-(o-tolylamino)-1,4-naphthoquinone 1f. 
                                                                                                    Spectroscopic data: Compound 1f 
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Expansion of the COSY NMR spectrum of 2-chloro-3-(o-tolylamino)-1,4-
naphthoquinone 1f. 
 
                                                                                                    Spectroscopic data: Compound 1f 
 
137 
 
 
        Full HSQC NMR spectrum of 2-chloro-3-(o-tolylamino)-1,4-naphthoquinone 1f. 
 
-CH3 
                                                                                                    Spectroscopic data: Compound 1f 
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Expansion of the HSQC NMR spectrum of 2-chloro-3-(o-tolylamino)-1,4-
naphthoquinone 1f. 
 
                                                                                                    Spectroscopic data: Compound 1f 
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HPLC-ESI-MS spectrum of 2-chloro-3-(o-tolylamino)-1,4-naphthoquinone 1f. 
 
                                                                                                    Spectroscopic data: Compound 1f 
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                IR (KBr, cm
-1
) spectrum of 2-chloro-3-(o-tolylamino)-1,4-naphthoquinone 1f. 
 
 
 
 
 
 
 
                                                                                                    Spectroscopic data: Compound 1g 
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COMPOUND 1g 
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1
H NMR (600MHz, CDCl3) spectrum of 2-chloro-3-(3-methoxyphenylamino)-1,4-naphthoquinone 
1g. The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 3-
methoxyaniline. Expansions of signals in the aromatic region are shown in the off-set plot. 
 
                                                                                                    Spectroscopic data: Compound 1g 
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13
C NMR (400MHz, CDCl3) spectrum of 2-chloro-3-(3-methoxyphenylamino)-1,4-
naphthoquinone 1g. Expansion of the signals between 126 ppm and 142 ppm are shown in the 
off-set plot. 
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                                                                                                    Spectroscopic data: Compound 1g 
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Full COSY NMR spectrum of 2-chloro-3-(3-methoxyphenylamino)-1,4-
naphthoquinone 1g. 
 
                                                                                                    Spectroscopic data: Compound 1g 
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 Expansion of the COSY NMR spectrum of 2-chloro-3-(3-methoxy-phenylamino)-
1,4-naphthoquinone 1g. 
 
                                                                                                    Spectroscopic data: Compound 1g 
 
145 
 
 
 
 
-OCH3 
Full HSQC NMR spectrum of 2-chloro-3-(3-methoxyphenylamino)-1,4-
naphthoquinone 1g. 
 
                                                                                                    Spectroscopic data: Compound 1g 
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Expansion of the HSQC NMR spectrum of 2-chloro-3-(3-methoxy-phenylamino)-
1,4-naphthoquinone 1g. The methoxy group correlation has been left out.  
 
                                                                                                    Spectroscopic data: Compound 1g 
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HPLC-ESI-MS spectrum of 2-chloro-3-(3-methoxy-phenylamino)-1,4-naphthoquinone 1g. 
 
                                                                                                    Spectroscopic data: Compound 1g 
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 IR (KBr, cm-1) spectrum of 2-chloro-3-(3-methoxy-phenylamino)-1,4-naphthoquinone 1g. 
 
                                                                                                    Spectroscopic data: Compound 1h 
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COMPOUND 1h 
 
 
                                                                                                                                                        
1
H NMR (600MHz, CDCl3) spectrum of the 2-chloro-3-(m-tolylamino)-1,4-naphthoquinone 1h. 
The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 3-methylaniline. 
Expansions of signals in the aromatic region are shown in the off-set plot. 
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                                                                                                    Spectroscopic data: Compound 1h 
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13
C NMR (400MHz, CDCl3) spectrum of 2-chloro-3-(m-tolylamino)-1,4-naphthoquinone 1h to 
show aromatic region. Expansion of the signals between 115 ppm and 142 ppm are shown in the 
off-set plot. 
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                                                                                                    Spectroscopic data: Compound 1h 
 
151 
 
  
       Full COSY NMR spectrum of 2-chloro-3-(m-tolylamino)-1,4-naphthoquinone 1h. 
 
                                                                                                    Spectroscopic data: Compound 1h 
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 Expansion of the COSY NMR spectrum of 2-chloro-3-(m-tolylamino)-1,4-naphtho-
quinone 1h showing the aromatic region only.  
 
                                                                                                    Spectroscopic data: Compound 1h 
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Full HSQC NMR spectrum of 2-chloro-3-(m-tolylamino)-1,4-naphthoquinone 1h. 
-CH3 
                                                                                                    Spectroscopic data: Compound 1h 
 
154 
 
 
  
 
 
 
 
 
 
 
 
 
 
Expansion of the HSQC NMR spectrum of 2-chloro-3-(m-tolylamino)-1,4-naphthoquinone 1h 
showing the aromatic region only. The methyl correlation has been left out.  
 
                                                                                                    Spectroscopic data: Compound 1h 
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HPLC-ESI-MS spectrum of 2-chloro-3-(m-tolylamino)-1,4-naphthoquinone 1h. 
                                                                                                    Spectroscopic data: Compound 1h 
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     IR (KBr, cm
-1
) spectrum of 2-chloro-3-(m-tolylamino)-1,4-naphthoquinone 1h. 
 
 
                                                                                                    Spectroscopic data: Compound 2a 
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COMPOUND 2a
 
1
H NMR (600MHz, CDCl3) spectrum of 2-chloro-3-phenoxy-1,4-naphthoquinone 2a. 
The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with phenol. 
Expansions of signals in the aromatic region are shown in the off-set plot. 
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                                                                                                    Spectroscopic data: Compound 2a 
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13
C NMR (150MHz, CDCl3) spectrum of 2-chloro-3-phenoxy-1,4naphthoquinone 2a. 
Expansion of the signals between 115 ppm and 180 ppm are shown in the off-set plot. 
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                                                                                                    Spectroscopic data: Compound 2a 
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Full COSY spectrum of 2-chloro-3-phenoxy-1,4-naphthoquinone 2a. 
                                                                                                    Spectroscopic data: Compound 2a 
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Expansion of the COSY spectrum of 2-chloro-3-phenoxy-1,4-naphthoquinone 2a. 
Diagonal  
                                                                                                    Spectroscopic data: Compound 2a 
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Full HSQC spectrum of 2-chloro-3-phenoxy-1,4-naphthoquinone 2a. 
                                                                                                    Spectroscopic data: Compound 2a 
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Expansion of the HSQC spectrum of 2-chloro-3-phenoxy-1,4-naphthoquinone 2a. 
 
 
 
 
 
 
 
 
                                                                                                    Spectroscopic data: Compound 2a 
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HPLC-ESI-MS spectrum of 2-chloro-3-phenoxy-1,4-naphthoquinone 2a. 
 
                                                                                                     Spectroscopic data: Compound 2b 
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COMPOUND 2b 
 
 
1
H NMR (600MHz, CDCl3) spectrum of 2-chloro-3-(2-chlorophenoxy)-1,4-naphthoquinone 2b. 
The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 2-chlorophenol. 
Expansions of signals in the aromatic region are shown in the off-set plot. 
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                                                                                                     Spectroscopic data: Compound 2b 
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13
C NMR (150MHz, CDCl3) spectrum of 2-chloro-3-(2-chlorophenoxy)-1,4-naphthoquinone 2b. 
Expansion of the signals between 118 ppm and 135 ppm are shown in the off-set plot. 
 
2x -C=O 
                                                                                                     Spectroscopic data: Compound 2b 
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              Full COSY NMR spectrum of 2-chloro-3-(2-chlorophenoxy)-1,4-naphthoquinone 2b. 
 
                                                                                                     Spectroscopic data: Compound 2b 
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Expansion of the COSY NMR spectrum of 2-chloro-3-(2-chloro-phenoxy)-1,4-
naphthoquinone 2b. 
 
 
                                                                                                     Spectroscopic data: Compound 2b 
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  Full HSQC NMR spectrum of 2-chloro-3-(2-chlorophenoxy)-1,4-naphthoquinone 2b. 
 
 
                                                                                                     Spectroscopic data: Compound 2b 
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Expansion of the HSQC NMR spectrum of 2-chloro-3-(2-chlorophenoxy)-1,4-
naphthoquinone 2b. 
 
 
 
 
 
 
 
 
 
 
                                                                                                     Spectroscopic data: Compound 2b 
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HPLC-ESI-MS spectrum of 2-chloro-3-(2-chlorophenoxy)-1,4-naphthoquinone 2b. 
 
 
 
                                                                                                     Spectroscopic data: Compound 2c 
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COMPOUND 2c 
 
 
 
 
1
H NMR (400MHz, CDCl3) spectrum of 2-chloro-3-(2-chloro-4-methylphenoxy)-1,4-
naphthoquinone 2c. The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone 
with 2-chloro-4-methylphenol. Expansions of signals in the aromatic region as well as the methyl 
signal are shown in the off-set plot. 
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                                                                                                     Spectroscopic data: Compound 2c 
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13
C NMR (100MHz, CDCl3) spectrum of 2-chloro-3-(2-chloro-4-methylphenoxy)-1,4-
naphthoquinone 2c. Expansion of the signals between 118 ppm and 136 ppm are shown in the 
off-set plot. 
 
-CH3 
2x -C=O 
                                                                                                     Spectroscopic data: Compound 2c 
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Full COSY NMR spectrum of 2-chloro-3-(2-chloro-4-methylphenoxy)-1,4-naphthoquinone 2c. 
 
                                                                                                     Spectroscopic data: Compound 2c 
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Expansion of the COSY NMR spectrum of 2-chloro-3-(2-chloro-4-methyl-phenoxy)-1,4-
naphthoquinone 2c. 
 
                                                                                                     Spectroscopic data: Compound 2c 
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-CH3 
 
Full HSQC NMR spectrum of 2-chloro-3-(2-chloro-4-methylphenoxy)-1,4-naphthoquinone 2c. 
 
                                                                                                     Spectroscopic data: Compound 2c 
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Expansion of the HSQC NMR spectrum of 2-chloro-3-(2-chloro-4-methyl-phenoxy)-1,4-
naphthoquinone 2c. The methyl cross-peak has been left out here.  
 
 
 
 
 
 
 
 
 
 
                                                                                                     Spectroscopic data: Compound 2c 
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HPLC-ESI-MS spectrum of 2-chloro-3-(2-chloro-4-methyl-phenoxy)-1,4-naphthoquinone 2c. 
 
                                                                                                     Spectroscopic data: Compound 2d 
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COMPOUND 2d 
 
 
 
1
H NMR (400MHz, CDCl3) spectrum of 2-chloro-3-(3,5-dimethylphenoxy)-1,4-naphthoquinone 
2d. The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 3,5-
dimethylphenol. Expansions of signals in the aromatic region as well as the methyl signal are 
shown in the off-set plot. 
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                                                                                                     Spectroscopic data: Compound 2d 
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13
C NMR (100MHz, CDCl3) spectrum of 2-chloro-3-(3,5-dimethyl-phenoxy)-1,4-
naphthoquinone 2d.   
 
 
 
 
 
 
 
 
 
-CH3 peak at 
21.36 ppm 
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                                                                                                     Spectroscopic data: Compound 2d 
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Full COSY NMR spectrum of 2-chloro-3-(3,5-dimethyl-phenoxy)-1,4-naphthoquinone 2d.   
 
                                                                                                     Spectroscopic data: Compound 2d 
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Expansion of the COSY NMR spectrum of 2-chloro-3-(3,5-dimethyl-phenoxy)-1,4-         
naphthoquinone 2d.   
 
                                                                                                     Spectroscopic data: Compound 2d 
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-CH3 
Full HSQC NMR spectrum of 2-chloro-3-(3,5-dimethylphenoxy)-1,4-naphthoquinone 2d.   
                                                                                                     Spectroscopic data: Compound 2d 
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Two carbon 
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Two carbon 
peaks, C6,C7 
 
CDCl3 
Expansion of HSQC NMR spectrum of 2-chloro-3-(3,5-dimethylphenoxy)-1,4-naphtho-
quinone 2d.  The methyl cross peak cannot be seen here.  
 
                                                                                                     Spectroscopic data: Compound 2d 
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HPLC-ESI-MS spectrum of 2-chloro-3-(3,5-dimethylphenoxy)-1,4-naphthoquinone 2d.   
 
                                                                                                    Spectroscopic data: Compound 2e 
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COMPOUND 2e 
 
 
1
H NMR (400MHz, CDCl3) spectrum of 2-chloro-3-(4-chlorophenoxy)-1,4-naphthoquinone 2e. 
The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 4-chlorophenol. 
Expansion of the aromatic region is shown in the off-set plot. 
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                                                                                                    Spectroscopic data: Compound 2e 
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13
C NMR (100MHz, CDCl3) spectrum of 2-chloro-3-(4-chlorophenoxy)-1,4-naphthoquinone 2e. 
Expansion of the signals between 118 ppm and 136 ppm are shown in the off-set plot. 
2x -C=O 
                                                                                                    Spectroscopic data: Compound 2e 
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Full COSY NMR spectrum of 2-chloro-3-(4-chlorophenoxy)-1,4-naphthoquinone 2e. 
 
                                                                                                    Spectroscopic data: Compound 2e 
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Expansion of the COSY NMR spectrum of 2-chloro-3-(4-chlorophenoxy)-1,4-
naphthoquinone 2e. 
 
                                                                                                    Spectroscopic data: Compound 2e 
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            Full HSQC NMR spectrum of 2-chloro-3-(4-chlorophenoxy)-1,4-naphthoquinone 2e. 
 
                                                                                                    Spectroscopic data: Compound 2e 
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Expansion of the HSQC NMR spectrum of 2-chloro-3-(4-chlorophenoxy)-1,4-
naphthoquinone 2e showing the aromatic region only. 
 
 
                                                                                                    Spectroscopic data: Compound 3a 
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COMPOUND 3a 
 
 
 
1
H NMR (600MHz, CDCl3) spectrum of 2,3-bis(phenylthio)-1,4-naphthoquinone 3a. The 
product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with thiophenol. 
Expansion of the aromatic region is shown in the off-set plot. 
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                                                                                                    Spectroscopic data: Compound 3a 
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13
C NMR (150MHz, CDCl3) spectrum of 2,3-bis(phenylthio)-1,4-naphthoquinone 3a. Expansion 
of the signals between 127 ppm and 134 ppm are shown in the off-set plot.  
2x -C=O 
                                                                                                    Spectroscopic data: Compound 3a 
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         Full COSY NMR spectrum of 2,3-bis(phenylthio)-1,4-naphthoquinone 3a. 
                                                                                                    Spectroscopic data: Compound 3a 
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Expansion of the COSY NMR spectrum of 2,3-bis(phenylthio)-1,4-naphthoquinone 3a. 
 
 
 
 
 
                                                                                                    Spectroscopic data: Compound 3a 
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Full of the HSQC NMR spectrum of 2,3-bis(phenylthio)-1,4-naphthoquinone 3a. 
                                                                                                    Spectroscopic data: Compound 3a 
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Expansion of the HSQC NMR spectrum of 2,3-bis(phenylthio)-1,4-naphthoquinone 3a. 
 
 
 
 
 
 
 
 
 
 
                                                                                                    Spectroscopic data: Compound 3a 
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HPLC-ESI-MS spectrum of 2,3-bis(phenylthio)-1,4-naphthoquinone 3a. 
 
                                                                                                     Spectroscopic data: Compound 3b 
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COMPOUND 3b 
 
 
 
1
H NMR (600MHz, CDCl3) spectrum of 2,3-bis(4-chlorophenylthio)-1,4-naphthoquinone 3b. 
The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 4-
chlorothiophenol. Expansion of the aromatic region is shown in the off-set plot. 
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                                                                                                     Spectroscopic data: Compound 3b 
 
199 
 
 
 
 
 
 
13
C NMR (150MHz, CDCl3) spectrum of 2,3-bis(4-chlorophenylthio)-1,4-naphthoquinone 3b. 
Expansion of the signals between 124 ppm and 135 ppm are shown in the first off-set plot. The 
second of-set plot is highlighting the quaternary carbon signal at 132.6 ppm.  
 
2x -C=O 
                                                                                                     Spectroscopic data: Compound 3b 
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Full COSY NMR spectrum of 2,3-bis(4-chlorophenylthio)-1,4-naphthoquinone 3b. 
 
 
 
 
                                                                                                     Spectroscopic data: Compound 3b 
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Expansion of the COSY NMR spectrum of 2,3-bis(4-chlorophenylthio)-1,4-
naphtho-quinone 3b. 
 
                                                                                                     Spectroscopic data: Compound 3b 
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                   Full HSQC NMR spectrum of 2,3-bis(4-chlorophenylthio)-1,4-naphthoquinone 3b. 
 
                                                                                                     Spectroscopic data: Compound 3b 
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Expansion of the HSQC NMR spectrum of 2,3-bis(4-chlorophenylthio)-1,4-naphtho-
quinone 3b. 
 
 
 
 
 
 
 
 
 
 
                                                                                                    Spectroscopic data: Compound 3c 
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COMPOUND 3c 
 
 
1
H NMR (600MHz, CDCl3) spectrum of 2,3-bis(4-bromophenylthio)-1,4-naphthoquinone 3c. 
The product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 4-bromo-
thiophenol. Expansion of the aromatic region is shown in the off-set plot. 
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                                                                                                    Spectroscopic data: Compound 3c 
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13
C NMR (150MHz, CDCl3) spectrum of 2,3-bis(4-bromophenylthio)-1,4-naphthoquinone 3c. 
Expansion of the signals between 132 ppm and 134 ppm are shown in the off-set plot. 
 
 
 
 
 
2x -C=O 
                                                                                                    Spectroscopic data: Compound 3c 
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                      Full COSY spectrum of 2,3-bis(4-bromophenylthio)-1,4-naphthoquinone 3c.  
 
                                                                                                    Spectroscopic data: Compound 3c 
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Expansion of the COSY spectrum of 2,3-bis(4-bromophenylthio)-1,4-naphthoquinone 3c. 
 
 
                                                                                                    Spectroscopic data: Compound 3c 
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         Full HSQC spectrum of 2,3-bis(4-bromophenylthio)-1,4-naphthoquinone 3c.  
 
                                                                                                    Spectroscopic data: Compound 3c 
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 Expansion of the HSQC spectrum of 2,3-bis(4-bromophenylthio)-1,4-naphthoquinone 3c.  
 
                                                                                                     Spectroscopic data: Compound 3d 
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COMPOUND 3d 
 
 
 
1
H NMR (600MHz, CDCl3) spectrum of 2,3-bis(p-tolylthio)-1,4-naphthoquinone 3d. The 
product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 4-methylthiophenol. 
Expansion of the aromatic region is shown in the off-set plot. 
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                                                                                                     Spectroscopic data: Compound 3d 
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13
C NMR (150MHz, CDCl3) spectrum of 2,3-bis(p-tolylthio)-1,4-naphthoquinone 3d. Expansion 
of the signals between 126 ppm and 138 ppm are shown in the off-set plot. 
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2x -CH3 
                                                                                                     Spectroscopic data: Compound 3d 
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      Full COSY NMR spectrum of 2,3-bis(p-tolylthio)-1,4-naphthoquinone 3d. 
                                                                                                     Spectroscopic data: Compound 3d 
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               Expansion of the COSY NMR spectrum of 2,3-bis(p-tolylthio)-1,4-naphthoquinone 3d. 
                                                                                                     Spectroscopic data: Compound 3d 
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      Full HSQC NMR spectrum of 2,3-bis(p-tolylthio)-1,4-naphthoquinone 3d. 
-CH3 
                                                                                                     Spectroscopic data: Compound 3d 
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          Expansion of the HSQC NMR spectrum of 2,3-bis(p-tolylthio)-1,4-naphthoquinone 3d. 
                                                                                                     Spectroscopic data: Compound 3e 
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COMPOUND 3e 
 
 
 
1
H NMR (600MHz, CDCl3) spectrum of 2,3-bis(o-tolylthio)-1,4-naphthoquinone 3e. The 
product was obtained from coupling 2,3-dichloro-1,4-naphthoquinone with 2-methyl-thiophenol. 
An expansion of the signals is shown in the off-set plot. 
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                                                                                                     Spectroscopic data: Compound 3e 
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13
C NMR (150MHz, CDCl3) spectrum of 2,3-bis(o-tolylthio)-1,4-naphthoquinone 3e. Expansion 
of the signals between 126 ppm and 134 ppm are shown in the off-set plot. 
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                                                                                                     Spectroscopic data: Compound 3e 
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          Full COSY NMR spectrum of 2,3-bis(o-tolylthio)-1,4-naphthoquinone 3e. 
 
                                                                                                     Spectroscopic data: Compound 3e 
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    Expansion of the COSY NMR spectrum of 2,3-bis(o-tolylthio)-1,4-naphthoquinone 3e. 
                                                                                                     Spectroscopic data: Compound 3e 
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     Full HSQC NMR spectrum of 2,3-bis(o-tolylthio)-1,4-naphthoquinone 3e. 
-CH3 
                                                                                                     Spectroscopic data: Compound 3e 
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Expansion of the HSQC NMR spectrum of 2,3-bis(o-tolylthio)-1,4-naphthoquinone. 
222 
 
Compound Id Supplier Id 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart Comment 
DDD00088272:01 Melarsoprol 68005 7.81 4.02 0.7 99.9 100.06 9.85E-08 6.07 
 
  
DDD01004774:01 
 
CC13(3)-24 
      1a 
68005 4.9 15.38 24.4 101.2 101.19 4.98E-05 12.07 
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Compound Id Supplier Id 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart 
 
DDD01004775:01 
 
CC13(3)-6 
1b 
68005 <4.3       54.88 4.98E-05 1224.55 
 
  
DDD01004776:01 
 
CC13(3)-11 
1c 
68005 4.96 1.92 18.1 103.1 97.98 4.98E-05 22.77 
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Compound Id Supplier Id 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart 
 
DDD01004777:01 
 
CC13(3)-15 
1d 
68005 5.61 4.93 -1.7 100.9 101.06 4.98E-05 17.13 
 
  
DDD01004778:01 
 
CC13(3)-40 
1e 
68005 5.67 2.59 1.1 98.5 102.15 1.64E-05 17.07 
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Compound Id Supplier Id 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart 
 
DDD01004779:01 
 
CC13(3)-46 
1f 
68005 5.55 5.18 -15.5 101.3 102.36 4.98E-05 8.52 
 
  
DDD01004780:01 
 
CC13(3)-53  
1g 
68005 5.6 6.08 -1.5 101.6 101.97 4.98E-05 5.4 
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Compound Id Supplier Id 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart 
 
DDD01004781:01 
 
CC13(3)-56 
1h 
68005 5.56 4.77 -8 101.1 101.17 4.98E-05 13.17 
 
  
DDD01004783:01 
 
CC13(2)-96 
2a 
68005 5.23 2.45 5.1 103.7 100.35 1.64E-05 19.17 
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Compound Id Supplier Id 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart 
 
DDD01004784:01 
 
CC13(3)-74 
2b 
68005 5.22 1.99 -1.5 106.2 100.42 1.64E-05 24.72 
 
  
DDD01004785:01 
 
CC13(3)-79 
2c 
68005 5.41 2.53 -8.3 101.7 100.49 1.64E-05 12.5 
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Compound Id Supplier Id 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart 
 
DDD01004786:01 
 
CC13(3)-60 
2d 
68005 5.27 1.28 0.8 111 100.16 1.64E-05 40.69 
 
  
DDD01004787:01 
 
CC13(3)-64 
2e 
68005 5.17 3.06 0.6 101.8 99.65 4.98E-05 20.98 
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Compound Id Supplier Id 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart 
 
DDD01004788:01 
 
CC13(2)-91 
3a 
68005 5.54 1.57 1.6 102.7 99.95 4.98E-05 11.13 
 
  
DDD01004789:01 
 
CC13(3)-68 
3b 
68005 4.49 2.23 24 100 79.01 4.98E-05 NaN 
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Compound Id Supplier Id 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart 
 
DDD01004790:01 
 
CC13(3)-88 
3c 
68005 <4.3       22.48 1.99E-06 5.21 
 
  
DDD01004791:01 
 
CC13(3)-90 
3d 
68005 5.14 2.22 11.3 101.1 100.64 4.98E-05 8.29 
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Compound Id
i
 Supplier Id
ii
 
Plate 
Id 
pEC50 
Hill 
slope 
Bottom Top 
Max 
Effect 
Max Effect 
Conc 
Top 
Confidence 
Interval 
                  Chart 
 
DDD01004792:01 
 
CC13(3)-92 
3e 
68005 <4.3       53.56 1.64E-05 NaN 
 
  
DDD01004793:01 
 
NQ 
(substrate) 
68005 5.14 4.12 -6.2 100 100.03 4.98E-05 20.47 
 
  
 
                                                   
i  Drug Discovery Unit, University of Dundee’s compound identification (ID) codes. 
ii Chikomborero Chakaingesu’s supplier ID codes where CC = initials, 13 = the year 2013, (2)/(3) = laboratory note book number and the last digits denote the page number.  
